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EXECUTIVE SUMMARY
This report documents the development and construction 
of a generic economic model for the healthcare services 
involved in prostate cancer treatment. It also presents 
findings of descriptive analyses on the disease burden and 
three cost-effectiveness analyses. Specifically, the objectives 
of this project were to:
 1. Build a generic economic model structure;
 2. Populate the model with data estimates; 
 3. Validate the generic model internally and externally;
 4.  Undertake descriptive analyses of costs and patient 
outcomes; and
 5.  Undertake three cost-effectiveness analyses 
comparing strategies of interest with the status quo and 
integrating the generic model structure.
A large comprehensive model was constructed in the 
computer package TreeAge Pro 2015 V2. The model is a 
Markov health state transition model with 17 health states and 
centres around four key health states: 1) very low- or low-risk, 
2) intermediate-risk, 3) high-risk to locally-advanced cancer, 
and 4) metastatic prostate cancer. There are health states 
for active treatments such as radiation, surgery, androgen 
deprivation therapy and for other management strategies 
such as active surveillance, watchful waiting, castrate-
resistant prostate cancer and palliation. The lifetime model 
ensures that treatment of relapse or progression is dependent 
on patient characteristics and previous treatments. It also 
includes the probabilities, health utilities (similar to quality 
of life) and costs of treatment complications. Two clinicians 
validated the model structure and the model predictions have 
been externally validated using Australian and international 
epidemiological trends in prostate cancer mortality, costs  
and health utilities.
Key findings from analysing the generic model include:
 —  On average, each case of prostate cancer has an 
estimated lifetime cost to the health system of $26,646, 
with the majority of costs incurred in the few years after 
being diagnosed.
 —  The lifetime cost of prostate cancer is less expensive 
for low-risk disease $19,681 and increases linearly by 
disease severity up to a case of metastatic disease 
costing $45,477.
Health services and treatments for prostate cancer are rapidly changing as researchers 
and clinicians look for better ways to control this disease. Over 20,000 men are diagnosed 
with prostate cancer each year and there is an estimated 200,000 men currently living with 
this disease in Australia. Consequently, prostate cancer is common and exerts a substantial 
burden to men and families affected by it. It also presents an immense challenge to the health 
system for planning of future services and we need to better understand the healthcare 
resources used in prostate cancer diagnosis and treatment and their impact.
 —  For privately insured men, the estimated out-of-pocket 
costs to men over the long term were on average 
$9,150 but this is highly dependent on physician fees. 
Out-of-pocket costs will be substantially lower for men 
treated in the public system. 
 —  The total estimated cost of prostate cancer treatment 
to the Australian health system in 2016 was  
$383.6 million rising to $543.9 million in 2025, an 
increase of 42%.
 —  For men diagnosed at age 65 years, age-adjusted 
survival was 87% at five years and 70% at 10 years. 
 —  With consideration of quality of life impacts and side 
effects of treatment, the average quality-adjusted 
life years were 7.8 per case of prostate cancer 
(discounted).
The three cost-effectiveness analyses performed addressed 
the following research questions:
 1.  What is the cost-effectiveness of multiparametric 
magnetic resonance imaging (mpMRI) with or without 
magnetic resonance (MR)-guided biopsy in the 
diagnosis of prostate cancer compared with the status 
quo?
 2.  What is the cost-effectiveness of increased uptake of 
active surveillance in eligible men with prostate cancer 
compared with the status quo?
 3.  What parameters would constitute cost-effective 
prostate-specific antigen (PSA) based screening of 
asymptomatic men for early detection of prostate 
cancer?
The results of these analyses, including thorough sensitivity 
analyses to address uncertainty of parameters and 
structures, are summarised in Table 1. They show that  
PSA screening and mpMRI are generally not cost effective 
and these results are driven by the lack of benefit for patients 
rather than high costs. PSA screening, if limited to two 
infrequent screens in young men (50 years), would be cost-
effective. Increased uptake of active surveillance is both cost-
saving and beneficial to patients in terms of quality-adjusted 
life years gained; however, these health gains are relatively 
small over the longer term.
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TABLE 1: SUMMARY OF COST-EFFECTIVENESS ANALYSIS FINDINGS
Intervention & comparator Cost-effective Probability of being 
cost-effective
1.  mpMRI with/without MR-guided biopsy versus TRUS-guided biopsy
  mpMRI with/without MR- or TRUS- or TPUS-guided biopsy versus  
TRUS-guided biopsy
No 
No
7.7% 
22.2%
2. Active surveillance: increased uptake versus current practice
  Active surveillance: increased uptake and partial uptake by men with 
intermediate risk cancers versus current practice
  Active surveillance: mpMRI selection to surveillance versus current practice
Yes
 
Yes
No
63.9%
 
75.6%
0.6%
3.  PSA screening, starting age 60 years, maximum of 2 screens  
4 years apart versus current practice
  PSA screening, starting age 50 years, maximum of 2 screens  
4 years apart versus current practice
 
No
 
Yes
 
20.0%
 
83.8%
mpMRI = multiparametric magnetic resonance imaging; MR-guided = magnetic resonance; PSA = prostate-specific antigen; TRUS = transrectal ultrasound
In summary, this large and detailed model of prostate cancer 
treatment from diagnosis to end-stage disease is operational 
and was adapted for three economic evaluations. The 
model uses contemporary sources and agrees well with 
observational data of prostate cancer in the UK and US giving 
confidence that the model is reliable. The main strength of this 
model is that it was designed and informed by high-quality 
clinical and economic evidence together with practising 
clinicians. This should ensure its relevance and currency 
in clinical practice. Health economics has a critical role in 
policy decisions for determining whether new treatments and 
services are cost-effective. This generic model is a flexible 
resource for assessing the cost-effectiveness of new and 
existing interventions in the management of prostate cancer. 
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1.0 PROJECT AIM & OBJECTIVES
The overall aim of this project was to provide 
health economic estimates of prostate cancer 
burden and the cost-effectiveness of a selection 
of existing and proposed new treatments or 
services for enhanced cancer control.
The overall aim of this project was to provide health 
economic estimates of prostate cancer burden and the cost-
effectiveness of a selection of existing and proposed new 
treatments or services for enhanced cancer control. 
The key project objectives were to:
 1. Build a generic economic model structure;
 2. Populate the model with data estimates; 
 3. Validate the generic model internally and externally;
 4.  Undertake descriptive analyses of costs and patient 
outcomes; and
 5.  Undertake three cost-effectiveness analyses 
comparing strategies of interest with current practice 
and integrating the generic model structure.
The following sections of the report provide the methods and 
results of these tasks.
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2.0  CONSTRUCTION OF GENERIC ECONOMIC 
MODEL FOR PROSTATE CANCER
2.1 MODEL DEVELOPMENT
Two literature reviews were undertaken at the outset of the 
project to: 1) identify Australian research on prostate cancer 
during the last 10 years; and 2) identify cost-effectiveness 
studies published on prostate cancer interventions during 
the last 15 years (see Appendix 1 for search details). These 
determined the current work that could inform the structure 
of our model and enabled an understanding of the Australian 
research into prostate cancer more broadly. Both searches 
provided guidance on the patterns of care provided to 
Australian men with prostate cancer, along with their patient 
outcomes. The economic studies undertaken were from any 
country and informed the structure of our model and the 
types of technologies tested. Clinical practice guidelines were 
reviewed to further understand the management options 
by risk stratification recommended from an international 
perspective  [1-4].
2.2 MODEL STRUCTURE
A Markov health state transition cohort model was built in 
TreeAge Pro 2015 V2. The model describes the patterns of 
care for diseases over long periods where patients can move 
between different specified health states. Both the health 
system costs and patient outcomes were assigned to the 
different health states in the model. Patients move through the 
model and face different probabilities of treatment pathways 
and outcomes. In this case, the model is based around the 
risk or stages of prostate cancer according to the US National 
Comprehensive Cancer Network Guidelines (2015)  [4].
There are 17 health states in the model starting at the point 
when a man has a confirmed diagnosis of prostate cancer. 
From here the first four health states are defined by clinical 
and test markers (i.e. tumour size (T), Gleason (Gl) scores and 
prostate-specific antigen (PSA)) as follows:
 1.  Very low and low risk (T1-T2a, Gl ≤6, PSA <10ng/ml);
 2.  Intermediate risk (T2b-T2c, Gl 7, PSA 10-20ng/ml);
 3.  High risk to locally advanced (T3-T4, Gl 8-10,  
PSA >20ng/ml);
 4.  Advanced disease (node positive, metastatic).
The model explicitly describes the health states that reflect 
typical treatments within the first two years after diagnosis 
when the majority of health care and resource use occurs. 
As shown in Figure 1, individuals will either receive curative 
treatments appropriate to the cancer stage or other 
management options that involve surveillance or palliative 
care. For very low and low-risk individuals, a proportion of 
men will undergo active surveillance or watchful waiting while 
the remaining will receive surgery or radiation (either external 
beam radiation therapy (EBRT) or brachytherapy). For 
intermediate and high-risk individuals, some men will undergo 
watchful waiting but most will receive active treatment. Major 
treatments in the first three health states include surgery and/
or radiation if indicated, radiation alone or following androgen 
deprivation therapy. Treatment for advanced disease consists 
of androgen deprivation therapy or if the patient experiences 
disease progression, therapies for castrate-resistant 
prostate cancer such as hormone manipulation and first-line 
chemotherapy. At any health state, over time men may also 
die from causes other than prostate cancer.
There are eight health states that describe subsequent health 
states after the first year of diagnosis, including:
 1. Post surgery (low risk);
 2. Post surgery (intermediate to high risk);
 3. Post radiation as first-line (low risk);
 4. Post radiation as first-line (intermediate to high risk);
 5. Post androgen deprivation therapy + radiation;
 6. Post surgery + radiation;
 7. Post first-line chemotherapy; and
 8. Post second-line chemotherapy.
These health states describe the care options after the first 
year of diagnosis and treatment while preserving the history 
of their first year treatment. The various treatments have 
different probability values associated with progression or 
stable disease. The remaining health states are:
 1. Castrate-resistant prostate cancer
 2. Active surveillance
 3. Watchful waiting 
 4. Palliative care
 5. Death
Except for ‘death’ in which no further transitions occur, 
patients in the above health states will remain in these unless 
their cancer progresses and they move into the relevant 
options of active treatment, advanced disease or they die.
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2.0  CONSTRUCTION OF GENERIC ECONOMIC 
MODEL FOR PROSTATE CANCER 
(continued)
Figure 1: Simplified schematic of generic economic model
ADT = androgen deprivation therapy; Int = intermediate
OTHER 
MANAGEMENT
CURATIVE 
TREATMENT
DIAGNOSIS
Very Low/Low Risk
Intermediate Risk
Death (all causes)
Advanced Cancer
(all receive ADT)
Active Surveillance
Watchful Waiting
Chemo 2nd Line
Palliative Care
Castrate Resistant 
Therapy
Low Risk Surgery
High/Int Risk, Radiation
High/Int Risk, Surgery
Radiation + ADT
Radiation + Surgery
High Risk
Note: All boxes/ovals are health states in the model. The four central boxes under diagnosis 
are health states and include rst-line treatment or management. Blue ovals are 
post-treatment health states where patients remain until death or disease progression occurs 
to increased risk states and subsequent management. The dashed lines indicate disease 
progression but this occurs (indirectly) following the treatment/management options. High risk 
disease includes ‘locally advanced’ disease also. Men can enter the death state at any time 
from any health state. 
Low Risk Radiation
Chemo 1st Line
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2.3 MODEL INPUTS
KEY MODEL SPECIFICATIONS
A number of key decisions were made on the basic structure 
of the model. These are detailed in Table 2.
TABLE 2: KEY STRUCTURAL ASSUMPTIONS
Input Value(s) Rationale
Cohort age 67% of men are aged 55-75 years with a mean of 
65 years. A normal distribution is applied. 
Median age of men diagnosed with prostate cancer 
in Australia is 65 years, tested over various age 
cohorts. 
Model duration Lifetime, maximum is when men reach age 90 
unless they die earlier
Lifetime to reflect long natural history of disease, 
and obtain long term outcomes/costs for ongoing 
therapies, model was tested over various durations
Discounting 5% costs and quality-adjusted life years, annually, 
life years remains undiscounted to reflect life 
expectancy 
Standard practice for Australian cost-effectiveness. 
Undiscounted results are also presented.
Cycles Annual Practical for lifetime model duration and many 
inputs are annual.
The key outputs of the model include:
 1. Health system costs;
 2. Life years (survival); and
 3. Quality-adjusted life years (QALYs).
The main categories of inputs in the model are broken down 
into probabilities, costs and utilities (similar to quality of life 
scores). These inputs are described in detail below.
PROBABILITIES 
Probability values were obtained from a systematic search of 
literature and included various study types; meta-analyses, 
randomised controlled trials, observational studies, as well 
as studies identified through Australian and international 
registries. Where appropriate, systematic reviews and meta-
analyses were preferred for studies reporting recurrence 
rates after different treatments [5-7], and high-quality studies 
reporting disease progression [8-11]. Table 3 summarises 
the final model transition probabilities with their values and 
sources. Where values were obtained for rates, such as 
mortality rates, these were converted into annual probabilities 
using the rate to probability formula; 1 – exp –rate x time. 
COSTS
The perspective used to determine the costs was that from 
the health system and physician fees were used as a proxy 
for costs of magnetic resonance imaging (MRI) which are 
increasingly used but not reimbursed by Medicare. Hospital 
costing reports and national Medicare reports (via the 
Medicare Benefits Schedule and Pharmaceutical Benefits 
Scheme) were used to value these resources. Other key 
studies and clinical guidelines identified in the literature review 
were used to identify resource types used for a particular 
treatment (Table 4). Costs were adjusted for inflation where 
necessary into 2015 values.
Separately, costs were considered for those borne by 
patients and families for healthcare services. These included 
out-of-pocket expenses for all aspects of healthcare 
services, therapies and medicines received from the time of 
diagnosis onwards. Additional costs for travel, parking and 
accommodation expenses are omitted but these can also be 
particularly substantial for persons living in rural and remote 
areas [12].
Appendix 2 provides the values and sources used for the 
analysis of patient costs. 
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2.0  CONSTRUCTION OF GENERIC ECONOMIC 
MODEL FOR PROSTATE CANCER 
(continued)
UTILITIES 
Health utilities are similar to health-related quality of life 
scores but specifically used in economic evaluations. The 
scores range from 0 to 1 with 0 representing death and 1 
representing best possible health status. The utility scores or 
weights are applied to survival to obtain the outcome ‘quality-
adjusted life years’ or QALYs. In the model, health utilities are 
applied to most health states and also disutilities are used 
for treatment complications. Table 5 provides details on the 
health utilities used in the model.
TABLE 5: HEALTH UTILITIES IN THE MODEL
Health state Value 95% CI / range Distribution Source
Low-risk disease 0.84 0.80, 0.88 Beta (281,54) Stewart (2005) and Stewart (2012) [26, 27]
Intermediate-risk disease 0.81 0.75, 0.87 Beta (138,32) Stewart (2005) and Stewart (2012) [26, 27]
High-risk to locally-advanced 
disease
0.71 0.65, 0.77 Beta (162,66) Stewart (2005) and Stewart (2012) [26, 27]
Advanced disease 0.67 0.61, 0.73 Beta (164,81) Stewart (2005) and Stewart (2012) [26, 27]
Castration resistant prostate 
cancer
0.40 0.30, 0.50 Beta (38,57) Hatoum (2013) and Bayoumi (2000) [28, 29]
Chemotherapy treatment 0.40 0.30, 0.50 Beta (38,57) Hatoum (2013) and Bayoumi (2000) [28, 29]
Palliative care 0.40 0.30, 0.50 Beta (38,57) Hatoum (2013) and Bayoumi (2000) [28, 29]
Observation (Watchful 
waiting)
0.80 0.77, 0.83 Beta (141,35) Australian norms for age >75 years, 0.85  
in Clemens (2014) [30]
Active surveillance 0.85 0.83, 0.87 Beta (1083,191) Australian norms for age 55-65 years, 0.85  
in Clemens (2014) [30]
Disutility from erectile 
dysfunction
0.05 0.03, 0.07 Gamma (25,500) From Cooperberg (2013), disutility was 0.1  
in two years [8]
Disutility from incontinence 0.10 0.05, 0.15 Gamma (4,40) From Cooperberg (2013), disutility was 0.2  
in two years [8]
CI = confidence interval
2.4 MODEL VALIDATION
The model was modified several times to improve the 
integrity of the key options but ensuring its efficiency. 
In-depth checking of all pathways occurred with two 
practising urologists. This provided face validation of the 
current structure, confirmed current Australian practice 
and resolved questions around best practice in Australia. 
Australian physicians adhere to the US practice guidelines 
by the National Comprehensive Cancer Network. Our model 
is currently based on these 2015 updated international 
guidelines [4].
The literature review identified several key studies that 
reported utility weights for relevant health states for patients 
with prostate cancer. The pivotal study by Stewart et al. 2005 
[24] provided utilities (using the standard gamble approach) 
from 162 men aged 60 years and over (52% of patients were 
diagnosed with prostate cancer). A systematic review and 
meta-analysis in 2007 [25] summarised the published evidence 
on health utilities for outcomes  
for prostate cancer.
The model was externally validated to ensure it produced 
outputs that are observed in other sources. This was 
achieved first for mortality data and visual assessment 
of survival curves by all men with prostate cancer and by 
severity of disease. Table 6 provides details on the survival 
proportion each year as men age in the general Australian 
population versus the men in the model with prostate cancer 
(all risk stages). These figures are illustrated in survival curves 
in Figure 2. The findings show that for men diagnosed with 
prostate cancer at age 65 years, the model predicts 5-year 
survival, relative to all men of the same age, at 96.6%,  
10-year survival at 90.1% and 20-year survival at 78.3%.
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TABLE 6: SURVIVAL PERCENTAGE OF MEN IN GENERAL POPULATION VERSUS MODEL POPULATION, BY AGE
Male age Survival in Australian men (ABS)a 
(men in general population)
Survival predicted by model 
(men with prostate cancer)
Relative survival, %
65 1 1
66 0.989098 0.984612 99.5%
67 0.977192 0.968734 99.1%
68 0.964178 0.949564 98.5%
69 0.949978 0.927566 97.6%
70 0.934498 0.903029 96.6%
71 0.917683 0.876257 95.5%
72 0.899430 0.847548 94.2%
73 0.879681 0.817204 92.9%
74 0.858335 0.785456 91.5%
75 0.835253 0.752470 90.1%
76 0.810287 0.718371 88.7%
77 0.783255 0.682776 87.2%
78 0.754021 0.646384 85.7%
79 0.722446 0.609451 84.4%
80 0.688439 0.572026 83.1%
81 0.651990 0.534111 81.9%
82 0.613120 0.495736 80.9%
83 0.572013 0.456993 79.9%
84 0.528908 0.418045 79.0%
85 0.484183 0.379140 78.3%
86 0.438350 0.340597 77.7%
87 0.392072 0.302837 77.2%
88 0.346147 0.266329 76.9%
89 0.301433 0.231555 76.8%
90 0.255000 0.198955 78.0%
ABS = Australian Bureau of Statistics, 3302.0.55.001 - Life Tables, States, Territories and Australia, 2011-2012
a Rates were converted into annual probabilities using the rate to probability formula; 1 – exp –rate x time
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2.0  CONSTRUCTION OF GENERIC ECONOMIC 
MODEL FOR PROSTATE CANCER 
(continued)
Figure 2: Survival curves for men in general population vs men with prostate cancer 
ABS = Australian Bureau of Statistics, 3302.0.55.001 - Life Tables, States, 
Territories and Australia, 2011-2012
A comparison of the modelled survival estimates and 
external sources of survival data in men with prostate cancer 
is provided in Table 7. The relative survival rate is thought 
to be a better indicator of the impact of prostate cancer 
because it recognises that men will die of other diseases in 
the general population. When the relative survival rate is over 
100%, it indicates that men are dying of other diseases more 
frequently than prostate cancer.
TABLE 7: COMPARISON OF SURVIVAL ESTIMATES FROM THE MODEL AND EXTERNAL SOURCES, ALL STAGES
Survival Model 
2015-2025
AIHW [31] 
2007-2011
SEER (US) 
2007-2011 [32]
SEER (US) [33] 
1973-2000
CRUK (UK) 
2006-2010
Canada 
2006-2008
1-year relative 99.3% 98.3% – – 94% –
5-year relative 95.5% 93.2% 100% 101.2% 99% 96%
10-year relative 87.9% – 99% 99.0% 94% –
Stage of cancer, 5-year relative survival 2002-2006
Low risk 99.7% n/a Local = 100% Stage I = 106.1% Stage I = 112% Local = 100%
Intermediate risk 98.5% n/a – Stage II = 105.1% Stage II = 99% –
High risk 95.9% n/a Regional = 100% Stage III & IV = 92.3% Stage III = 93% Regional = 100%
Advanced 35% n/a Advanced = 28% Advanced = 31.3% Stage IV = 30% Advanced = 31%
Data sources: AIHW 2014 [31], SEER US [32], SEER US [33], Cancer Research UK [34], Canada Cancer Society[35]
AIHW = Australian Institute of Health and Welfare; CRUK = Cancer Research UK; n/a = not applicable; SEER = Surveillance, Epidemiology, and End Results Program; 
When the relative survival rate is over 100%, it means men are dying of other diseases more frequently than prostate cancer.
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The modelled survival estimates are similar or slightly higher 
than those from external sources. This seems appropriate 
as the model reflects estimated survival going forward in 
time and should reflect improvements gained from recently 
approved treatments in advanced disease but would not be 
revealed in the external sources of past survival. However, the 
modelled estimates are not so different that the incremental 
differences are not implausible. Stage-specific survival 
curves predicted by the model are presented in Figure 3.
Figure 3: Stage-specific survival curves predicted from model for men aged 65 years
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2.0  CONSTRUCTION OF GENERIC ECONOMIC 
MODEL FOR PROSTATE CANCER 
(continued)
Figure 4 illustrates the costs predicted by the model for 
prostate cancer overall and by cancer risk. This shows that 
costs mostly accumulate in the early years of the disease and 
differ depending on stage of disease with costs highest for 
advanced cancer and lowest for low-risk disease.
Figure 4: Cumulative prostate cancer cost from a health system perspective (AU$ 2015)
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Costs were considered for two time horizons; 1) the first 
12 months from diagnosis and 2) lifetime costs of prostate 
cancer. The model predicted that the average cost for the 
first year of treatment was AU$13,264 for all stages. In 
another Australian study, the per-patient direct health care 
cost was 2015 AU$20,118 relating to 2005 resources [36]. 
The cost for the first year of treatment from two Canadian 
studies [37, 38] that were 2004 CAD 8,636 (2015 AU$13,772) up 
to 2004 CAD 17,067 (2015 AU$23,939). Two studies from the 
US [23, 39] reported higher costs in the first year of treatment 
between USD 9,000-10,612 (2015 AU$ 17,412 to $20,531). The 
model predicted that the cumulative lifetime cost of cancer 
treatment for all stages was AU$26,646. 
Figure 4 illustrates the cumulative cost for each disease stage 
over the model duration, and this confirms the concentration 
of costs in the early years but also the higher-cost treatments 
for more advanced disease, in agreement with other findings 
[37, 40].
The health utilities used in the model were validated with 
those obtained from the Victorian Cancer Registry (patient-
level data, unpublished) where health utilities were collected 
on the SF-6D utility tool (see Table 8). The values used in the 
model were derived from the standard gamble method and so 
some differences may be expected due different populations 
and utility survey tools.
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TABLE 8: COMPARISON OF THE UTILITIES IN OUR MODEL WITH VICTORIAN CANCER REGISTRY DATA
Model Victorian Cancer Registry data
Health state Value 95% CI n Value 95% CI
Low-risk disease 0.84 0.80, 0.88 1743 0.81 0.81, 0.82
Intermediate-risk disease 0.81 0.75, 0.87 3071 0.80 0.80, 0.81
High-risk to locally-advanced disease 0.71 0.65, 0.77 1595 0.77 0.77, 0.78
Advanced disease 0.67 0.61, 0.73 203 0.72 0.70, 0.74
Castration resistant prostate cancer 0.40 0.30, 0.50 26 0.61 0.56, 0.67
Chemotherapy treatment 0.40 0.30, 0.50 57 0.63 0.59, 0.67
Palliative care 0.40 0.30, 0.50 84 0.68 0.64, 0.71
Observation (watchful waiting) 0.80 0.77, 0.83 246 0.75 0.74, 0.77
Active surveillance 0.85 0.83, 0.87 1219 0.81 0.80, 0.82
Disutility from erectile dysfunction 0.05 0.03, 0.07 a – –
Disutility from incontinence 0.10 0.05, 0.15 a – –
CI = confidence interval; VCR = Victorian Cancer Registry data
Bold = VCR values are substantially different
a Estimated range
The estimates for the utilities derived from the SF-6D tool 
(using selected items from the SF-36 survey) were very 
similar to six values in our model and were mostly within the 
95% confidence interval (CI) ranges specified in the model. 
Most importantly, the values for the first four key health 
states of disease risk are consistent between the two sets 
of values. However, the mean utility estimates for the health 
states chemotherapy, castrate-resistant prostate cancer and 
palliative care were higher in the Victorian registry data than 
those used in the model by approximately 0.20. The reason 
for this variation is unknown. In order to remain consistent 
with estimates from the literature, the model used estimates 
derived from the Hatoum et al. (2013) and Bayoumi et al. 
(2000) studies [28, 29].
2.5 ANALYSES
The model was analysed by an expected value analysis. 
The probabilities, costs, survival and health utilities were 
aggregated across all branches and mean values derived. 
Due to the model predicting outcomes into the future,  
across the remaining lifetime, ‘discounting’ was applied.  
This accounts for time preferences and brings values back  
to the present. Discounting is standard practice for long-term 
economic modelling (beyond one year) but it means that 
programs where benefits that occur in the future may  
be penalised. Therefore, undiscounted results are important 
also for screening and prevention programs.
One-way sensitivity analyses were performed to determine 
the key variables of the economic model and their influence 
on the stability of the results in the base case. This was 
achieved by re-analysing the model with one variable 
varied each time, usually over the 95% confidence limit or 
other plausible range. In multivariate analyses, probabilistic 
sensitivity analyses were undertaken and this involved 
random sampling of all model inputs simultaneously from 
their assigned distributions. This technique addresses 
parameter uncertainty and the stability of the base case 
results. Distributions were assigned to reflect uncertainty 
with the values in the model. Beta distributions were 
assigned to probabilities and utilities, gamma distributions 
to costs and Dirichlet distributions were assigned to a set of 
treatment options. A total of either 1000 or 5000 Monte Carlo 
simulations were performed and the means and standard 
deviations extracted. 
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3.1 KEY OUTCOMES
Key outcomes of the model are provided in Table 9 for 
mean costs, mean QALYs and mean life years (or survival), 
and by different age cohorts and disease stage. The model 
predicted mean QALYs of 7.8 (standard deviation (SD) 1.7). 
Clinically-localised disease (including locally-advanced 
cancer) represented 97% of the all new cases and had 
an average treatment cost of $26,109 (SD $4,730) over a 
lifetime. This contrasts with advanced disease representing 
3% of new cases with an average cost of $45,477 (SD 
$3,697) over remaining life. The highest cumulative cost for 
advanced disease was $45,477 followed by high-risk $37,349, 
intermediate-risk $24,442, and low-risk disease $19,681.
TABLE 9: KEY OUTCOMES OF THE ECONOMIC MODEL OVER REMAINING LIFE a
Mean cost (SD) Mean QALYs (SD) Mean life years (SD)
Base case (discounted) $26,646 ($4,414) 7.8 (1.7) n/a
Base case, undiscounted $34,794 ($7,898) 12.6 (4.1) 16.4 (0.1)
Cohorts with different mean age b:
  50 years mean $32,400 ($1,717) 10.0 (0.2) 24.9 (0.3)
  55 years mean $30,824 ($1,764) 9.5 (0.2) 22.1 (0.2)
  60 years mean $28,989 ($1,647) 8.8 (0.2) 19.3 (0.1)
  70 years mean $24,278 ($1,384) 6.9 (0.1) 13.4 (0.1)
  75 years mean $20,785 ($1,273) 5.7 (0.1) 10.4 (0.04)
  80 years mean $18,153 ($1,122) 4.3 (0.1) 7.5 (0.02)
Stage of disease
Localised cancer $26,109 ($4,730) 8.0 (1.8) 16.8 (0.1)
  Very low / low risk $19,681 ($4,639) 9.0 (2.2) 18.1 (0.1)
  Intermediate risk $24,442 ($4,477) 8.3 (1.8) 17.0 (0.1)
  High risk to locally advanced $37,349 ($5,212) 6.6 (1.2) 14.7 (0.4)
Advanced cancer $45,477 ($3,697) 1.7 (0.1) 4.0 (0.1)
n/a = not applicable; SD = standard deviation; QALYs = quality-adjusted life years
a All figures are from probabilistic sensitivity analysis outcomes from 1000 Monte Carlo simulations. 
b The base case uses a mean of age 65 years.
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The results in Table 9 indicate that the health system cost for 
each case of prostate cancer, is on average $26,646 per case. 
The cost per case is more expensive as disease becomes 
more advanced and this is directly a function of more 
therapies and more expensive therapies associated with 
progressed disease. Costs are somewhat higher for men who 
are younger; however, these should be viewed with caution 
as with any lifetime model, costs are heavily dependent on 
longer survival and the ongoing monitoring costs accruing 
with age. Currently the model has no option for exiting follow-
up care and men will be followed-up for their remaining life. 
It is uncertain if this would be the case in all men. At all ages 
(mostly over 40 years), men can be diagnosed with either 
localised or advanced cancer. As Figure 4 shows, costs 
mostly accumulate in the early years of the disease and 
depend on stage of disease. 
ADT = androgen deprivation therapy; adv = advanced; dx = diagnosis;  
EV = expected value; int = intermediate; Prob = Probability; rad = radiation
Figure 5: Tornado diagram of the most influential variables in the model
Sensitivity analyses allow interrogation of the model inputs 
and their relative contribution to the results. One-way 
sensitivity analyses were undertaken on all variables where 
uncertainty was possible for that value. The model was re-run 
with one variable value varied and the results observed. The 
values tested are the ranges in Tables 3 to 5 and they are 
mainly the high and low 95% confidence limits.
The key drivers of the model were: the health utility 
scores and probabilities of very low- to low-risk disease, 
intermediate-risk disease and high- to locally-advanced 
disease  (Figure 5). These were followed by the probabilities 
of recurrence after surgery and radiation, first-line radiation 
for intermediate- or high-risk patients and after first-line 
androgen deprivation therapy. When these values varied 
over their respective high and low estimates, they made the 
greatest impact on the results (Figure 5).
In Figure 5, the vertical line represents the expected net 
monetary value of $369,228. This is calculated by the $50,000 
willingness-to-pay for one QALY gain multiplied by the mean 
QALYs (7.92) minus mean costs ($26,769). The mean costs 
and QALYs are not from the Monte Carlo simulations but a 
simple expected values calculation. The bars to either side 
of the vertical line are the variation in the net monetary value 
from the high and low values tested. As indicated, at most 
these vary between $361,000 and $378,000.
360,000 362,000 364,000 366,000 368,000 370,000
EV: 369227.6720337607
372,000 374,000 376,000 378,000 380,000
Utility scores for very low risk (0.8 to 0.88) 
Prob dx with very low to low risk cancer (0.27 to 0.31)
Prob dx with intermediate risk cancer (0.42 to 0.46)
Utility scores for high to locally adv risk (0.65 to 0.77)
Prob dx with high to locally adv risk (0.22 to 0.26)
Utility scores for intermediate risk (0.75 to 0.87)
Prob of recurrence after surgery+radiation (0.04 to 0.08)
Prob recurrence after 1st line rad – int/high risk (0.02 to 0.06)
Disutility from erectile dysfunction (0.03 to 0.07)
Prob develop symptoms on observation (0.02 to 0.04)
Prob of recurrence after radiation treatment as 1st line 
in low risk patients (0.005 to 0.04)
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3.2 EXTRAPOLATION OF COSTS AUSTRALIA-WIDE
To estimate the health system costs of prostate cancer over 
the next 10 years in Australia, data were extrapolated using 
the following approach:
 1.  The estimated prevalence of prostate cancer for 2016 
was extracted from a study by Yu et al. (2015) where the 
number of prevalent cases in Australia were estimated 
at between 185,700 to 201,700 in 2017 [41]. The low 
value of 185,700 was used from 2016 onwards. An 
average age of prevalent men of 65 years was assumed 
and mortality was accounted for as predicted by our 
model. An average cost of $478 per year was applied 
for the ongoing costs of follow-up, also taken from our 
modelled costs, being the average of the last 20 years 
of the model.
 2.  Incidence of prostate cancer was obtained from the 
Australian Institute of Health and Welfare (AIHW) 
Australian Cancer Incidence and Mortality Book for 
prostate cancer [42]. This was used to predict the trend 
of new cases of prostate cancer over the next 10 years 
and assumes that current ad hoc PSA screening and 
population growth continues at current levels. Expected 
incidence was obtained by 5-year age group level.
TABLE 10:  ESTIMATED NUMBERS OF MEN AND AUSTRALIA-WIDE COSTS OF MEN WITH PROSTATE CANCER ($ MILLION)
Stage 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Estimated numbers of men with prostate cancer
Prevalent mena 185,700 182,361 175,925 165,973 152,547 136,117 117,534 97,908 78,452 60,289
Low risk 5,437 10,935 16,427 21,842 27,107 32,148 36,897 41,295 45,299 48,882
Intermediate risk 9,630 19,364 29,087 38,646 47,868 56,576 64,613 71,857 78,241 83,751
High riskb 6,150 12,374 18,596 24,685 30,475 35,801 40,524 44,566 47,916 50,628
Advanced 1,089 1,962 2,523 2,820 2,967 3,054 3,125 3,193 3,260 3,328
Total 208,006 226,996 242,558 253,966 260,963 263,695 262,692 258,820 253,168 246,878
Estimated healthcare costs of men with prostate cancer ($ million)
Prevalent casesa 88.8 87.2 84.1 79.3 72.9 65.1 56.2 46.8 37.5 28.8
Low risk 48.5 48.5 53.0 59.0 64.6 70.0 78.3 83.2 87.7 91.8
Intermediate risk 131.5 131.5 139.8 147.9 156.8 166.2 181.5 190.5 198.8 206.1
High riskb 108.3 108.3 112.7 119.8 128.7 138.3 154.8 163.8 171.7 178.4
Advanced 6.5 6.5 14.7 19.0 20.9 21.7 22.3 22.8 23.3 23.8
Total ($millions) 383.6 407.3 429.8 450.4 469.1 502.1 516.5 528.3 537.6 543.9
a All risk stages
b Includes locally-advanced cancer
 3.  Victorian Cancer Registry data were analysed to obtain 
the proportion of men within each disease risk category 
(i.e. very low/low-risk, intermediate-risk, high-risk + 
locally-advanced and metastatic disease) by the 5-year 
age group (n=8,065).
 4.  The expected cases of prostate cancer within each 
disease risk and age group was estimated as the 
product of the AIHW and Victorian registry data.
 5.  The annual costs of the first 10 years of treatment were 
derived from the model, separately for each disease 
risk and multiplied by expected numbers of new cases. 
Average cost for all prostate cancer was applied to the 
prevalent cases. 
Using the expected mortality rates predicted by the generic 
model, all estimates were adjusted for mortality from prostate 
cancer and other causes. The results are provided in  
Table 10 and Figure 6. As expected, the estimates presented 
here beginning in 2016 are higher than those last reported 
by the AIHW; $346.6 million in 2008/09 or 7.7% of all cancer 
expenditure [43].
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Using our generic model and other sources, the total 
estimated healthcare costs of prostate cancer treatment in 
2016 was $383.6 million rising to $543.9 million in 2025, an 
expected increase of 42% in the next 10 years. 
Men aged in the two most common age groups for diagnosis 
of prostate cancer 60-64 years and 65-69 years are expected 
to have the most growth in healthcare costs over the next  
10 years.
Figure 6: Total first year costs of prostate cancer treatment by 5-year age group (2016 and 2025)
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Costs in the first year of prostate cancer are substantial where 
the majority of the key treatments occur, compared with 
following years. Figure 6 presents the calculated costs, for 
each risk stage and by each 5-year age group based on the 
expected cases for 2016 and 2025. 
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4.0 OVERVIEW OF ECONOMIC EVALUATIONS
In the following sections, three economic evaluations 
are reported. The topics of these analyses include cost-
effectiveness and cost-utility analyses of the following:
 1.  Multiparametric magnetic resonance imaging  
(mpMRI) for diagnosis of prostate cancer; 
 2.  Active surveillance strategies for low-risk prostate 
cancer; and
 3. PSA screening for early detection of prostate cancer.
The three economic evaluations are reported over four  
sub-sections including a background and rationale, methods, 
results and discussion. In addition, the separate sections 
end with ‘The Bottom Line’ summary of the findings. Some 
commonalities across the studies are mentioned here with 
the intervention specifics further detailed in the following 
sections. 
The generic model was used in all analyses and altered to 
specifically address the research questions. These alterations 
are fully detailed and consequently, three unique models 
were developed, which are named the mpMRI model, the 
active surveillance model and the PSA screening model. 
Accompanying these structural changes are additional 
data inputs. These were sourced from literature searches 
and the best available evidence at hand. Additional costs 
were obtained from hospital costing reports, the Medicare 
Benefits Schedule and Pharmaceutical Benefits Schedule. 
When costs were derived from international sources and in 
a preceding time period, the costs were corrected to 2015 
Australian dollars. Future benefits and costs were discounted 
at 5% per year to reflect time preference. Half-cycle 
corrections were also applied. 
In all analyses, the main outcomes reported were healthcare 
costs, QALYs and life years. Other outcomes were added 
where relevant. The main measure from cost-effectiveness 
analyses is the incremental cost-effectiveness ratio (ICER) 
and the formula is:
ICER =   
Cost (Intervention) — Cost (Current Scenario) 
               Effect (Intervention) — Effect (Current Scenario)
The ICER is the difference in costs between the intervention 
of interest and the current scenario divided by the 
difference in effects (i.e. QALYs and life years). Because new 
interventions usually cost more and give additional patient 
benefits, the ICER can be interpreted as the additional costs 
of the new intervention in relation to the additional benefits. 
In Australia, when the ICER is up to $50,000 per QALY or life 
year saved, in general the new intervention is considered 
cost-effective. If costs of the intervention are less than 
those for the current scenario, and effects are higher, the 
intervention is said to be superior. Conversely, if costs are 
higher and effects lower, the intervention is inferior to the 
current scenario.
One-way and probabilistic sensitivity analyses were 
performed as explained in Section 2.5. The Monte Carlo 
simulation findings were presented in cost-effectiveness 
acceptability curves and incremental cost-effectiveness 
scatter plots and the interpretation of these diagrams is 
provided.
4.1  COST-EFFECTIVENESS ANALYSIS OF 
MULTIPARAMETRIC MRI 
BACKGROUND & RATIONALE
The presence of prostate cancer is normally assessed 
with a PSA test and/or DRE. If cancer is suspected, a 
transrectal ultrasound (TRUS)-guided biopsy followed by 
histopathological grading (Gleason score) is performed 
to confirm a diagnosis. However, TRUS/ Gleason score 
approach does not always distinguish well between 
serious, clinically significant prostate tumours and clinically 
insignificant tumours. Consequently, the combined low 
sensitivity of PSA and DRE tests for prostate cancer has 
led to the over detection and subsequent over treatment 
of clinically insignificant prostate cancers. Problematically, 
there is also under treatment of the clinically significant 
prostate cancers. Recent evidence suggests that mpMRI 
could increase the accuracy of detecting clinically significant 
prostate cancer, and in the process, reduce the need to 
perform biopsies [44] of indolent tumours. Potentially, a more 
targeted less-invasive approach for patients is mpMRI which 
is thought to improve the efficiency of the current diagnostic 
pathway [45]. In general, when mpMRI is offered and it is 
positive for prostate cancer, a confirmatory biopsy is still 
necessary. Alternative types of biopsies are used by clinicians 
in Australia including TRUS-, transperineal ultrasound 
(TPUS)- and MR-guided biopsy.
Clinicians have identified three potential roles for mpMRI in 
prostate cancer management including:
 1.  To guide patient selection for initial biopsy (biopsy naïve 
patients);
 2. To guide patient selection for repeat biopsy; and
 3.  To guide patient selection in active surveillance of very 
low- to low-risk prostate  
cancers [46].
The current clinical guidelines in Australia recommend the 
consideration of mpMRI for men in the repeat biopsy stage, 
that is, men remaining at risk of prostate cancer despite 
a prior negative TRUS-guided biopsy [1]. This is due to the 
concern that men given the ‘all clear’ from first TRUS biopsy 
remain at risk of harbouring clinically significant disease.  
A systematic review showed MRI-guided biopsies detect 
16% more clinically significant prostate cancers compared 
with TRUS-guided biopsy [47]. 
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Where mpMRI is available in centres throughout Australia, 
men with suspected prostate cancer can receive mpMRI in 
the private system at an out-of-pocket cost of ~$500-$600. 
There is no reimbursement of this fee through Medicare. 
However, there is a current submission to the Medical 
Services Advisory Committee (MSAC) from the Urological 
Society of Australia and New Zealand for government 
reimbursement of mpMRI with or without a subsequent  
MR-guided biopsy, for patients who are biopsy naïve  
but suspected of prostate cancer through abnormal  
PSA/ DRE [48]. 
Multiparametric MRI is a reasonably new technology that 
has existed for less than five years although many consider 
it standard practice in Australia and elsewhere around the 
world. However, there is still uncertainty around issues 
such as the best MRI-guided biopsy approach to use after 
lesion detection on mpMRI (MRI-in bore, MRI-TRUS fusion); 
whether to use mpMRI with or without MRI-guided biopsy as 
a substitute or a complement to the standard TRUS-guided 
biopsy; and the possible cost-effectiveness of introducing 
an expensive technology like MRI for the detection of 
prostate cancer. The aim of this study was to perform a cost-
effectiveness analysis comparing two MR-based strategies 
versus a TRUS-based strategy in Australia for men suspected 
for prostate cancer but who have not had a prior biopsy (that 
is, they are biopsy naïve). This population of men matches 
that proposed by the current MSAC application. 
METHODS
Our generic economic model was modified to evaluate 
the diagnostic accuracy, quality of life, patient survival and 
economic costs associated with three strategies. Specifically, 
the model compared:
 Strategy 1: no mpMRI and TRUS-guided biopsy;
 Strategy 2: mpMRI with or without MR-guided biopsy; and
 Strategy 3:  mpMRI with or without either TRUS-, TPUS- or 
MR-guided biopsy.
In the mpMRI strategies, patients with a suspected prostate 
cancer will receive a biopsy but only one repeat biopsy is 
required for a negative mpMRI result, where PSA and/or DRE 
still indicate cancer may be present. Strategy 3 is intended 
to reflect current practice where either of the three types of 
biopsies are performed depending on clinician preferences.
The TRUS-guided biopsy with 21-24 sextant cores is 
currently recommended for definitive diagnosis of prostate 
cancer [1]. Both the transrectal and transperineal approaches 
are accepted choices and are equivalent in both efficacy and 
safety [49]. There are several published studies on the cost-
effectiveness of mpMRI versus TRUS-guided biopsy but they 
differ slightly in their targeted populations including biopsy 
naïve, prior biopsy or a mixed population of both. They also 
differ in their model structures which cover the diagnostic 
phase only with no longer-term downstream effects [44, 50-52]  
as possible with our generic model.
Building on the generic model, the mpMRI model structure 
has three additional health states that are depicted in Figure 7 
for Strategy 1. The three additional health states are:
 1.  Biopsy naïve: In Strategy 1, all men with elevated 
PSA and/or suspicious DRE are given a TRUS-guided 
biopsy. This would reveal the presence or absence of 
cancer. In those suspected to have cancer, branches 
representing low-, intermediate-and high-risk cancer 
are added. Each cancer risk branch has sub-branches 
representing the subsequent diagnostic accuracy of the 
TRUS-guided biopsy. 
 2.  PCa negative, Missed PCa: In those men who actually 
do have cancer but the biopsy is found to be negative 
(false negatives), these men remain with elevated PSA 
and undergo one only repeat biopsy (all receive TRUS). 
The model assumes that if the cancer is not accurately 
detected after the second biopsy, the man would 
continue to be monitored (moving to the ‘PCA negative: 
PSA monitor’ arm) but no further biopsies occur. 
 3.  PCa negative, PSA monitor: Men who truly do not 
have cancer (true negatives) also receive a confirmatory 
repeat biopsy and thereafter continue to be monitored 
with PSA and/or DRE tests only. The risk of cancer can 
occur in a small proportion of men during this follow-up 
period while receiving regular PSA tests. This risk is 
spread over two decades.
When prostate cancer is detected, the men enter the existing 
health states of the generic model and receive all treatments 
and follow-up relevant to their stage of cancer.
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The model structure also has three additional health states 
for the MR strategies, which are shown in Figure 8. The only 
difference between these two strategies are the types of 
biopsies performed and their relative diagnostic performance. 
The three additional health states are:
 1.  Biopsy naïve: In Strategies 2 and 3, all men with 
elevated PSA and/or suspicious DRE are given an 
mpMRI scan. This provides a positive or negative result 
for the presence or absence of cancer. In those believed 
to have cancer, the men would proceed to a MR-guided 
biopsy (Strategy 2) or either a TRUS, TPUS or MR-
guided biopsy (a weighted figure for 33.3% of each 
type was assumed) (Strategy 3). Men with a positive 
result for cancer are stratified by risk of cancer and the 
subsequent diagnostic accuracy of the MR-guided 
biopsy (Strategy 2), or weighted accuracy figures for 
TRUS, TPUS or MR-guided biopsy. If men have a false 
negative result for cancer, they will go to the ‘PCa 
negative: Missed PCa’ health state or, if they are truly 
negative, to the ‘PCA negative: PSA monitor’ health 
state.
 2.  PCa negative: Missed PCa: This is identical to Strategy 
1 described earlier.
 3.  PCa negative: PSA monitor: This is identical to Strategy 
1 described earlier.
As previously, when prostate cancer is detected, the 
men enter the generic model health states and receive all 
treatments and follow up as per standard care.
The transitional probabilities, diagnostic accuracy of 
screening tests, costs and utilities/disutilities were obtained 
from a literature review (Table 11). An Australian study by 
Thompson et al. (2014) [53] was used to populate most of the 
key estimates of mpMRI diagnostic accuracy in our model 
and were similar to those reported in a recent systematic 
review [45]. The Thompson (2014) study was a single-centre, 
prospective diagnostic study analysing 150 consecutive men 
(88% were biopsy-naïve) recruited through two urologists in 
Sydney, Australia (April 2012 to April 2013). The type of MR-
guided biopsy used was either MRI/TRUS fusion or cognitive 
MR, both transperineal. The index test was transperineal 
ultrasound biopsy. This study was selected because it 
was Australian, reflected current local practice and it was 
reasonably consistent with the population of biopsy naïve 
men. Although Pokorny et al. (2014) also included biopsy 
naïve men [54], the negative predictive value (~97%) may be 
over-stated because of the inclusion of men with Gleason 7 
cancers. Schoots et al. (2014) systematic review was used to 
complete the sensitivity and specificity values not available in 
Thompson and the TRUS was used as the index test (n=1657 
cancers). A limitation of these pooled estimates was the high 
heterogeneity across studies (Table 11).
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For the mpMRI model, the cancer prevalence, the proportion 
of insignificant tumours (very low or low risk) and significant 
tumours (intermediate risk and above) were obtained 
from Thompson et al. (2014). The probability of men being 
diagnosed with prostate cancer after negative tests and 
biopsies was assumed to be similar to the rate captured over 
2.8 years, from Gann et al. (2010) [55]. A rate-to-probability 
formula was applied and resulted in a probability of 9.7% per 
year. Similarly, deaths from men being monitored on a PSA 
testing regimen were based on observational data captured 
over 13 years from the European Randomized Study of 
Screening for Prostate Cancer (0.38% per year) [56]. 
Prostate biopsies can be associated with adverse events 
in some men, namely, bleeding, pain, infections, sepsis, 
vasovagal episodes, erectile dysfunction as well as anxiety 
[51, 57]. No studies were found that reported health utilities 
for any type of biopsy. It is unclear whether an MR-guided 
biopsy would be any different to TPUS- or TRUS-guided 
biopsy in terms of the temporary impact on quality of life. 
In a cost-utility analysis by Zhang et al. (2012) a disutility of 
0.05 was used but originally came from a study on sentinel 
lymph node biopsy for breast cancer [58, 59]. The MR approach 
uses fewer needles (2 to 4 cores) than the TRUS-guided 
biopsy (12-32 cores). Because fewer cores are taken during 
the MR-guided approach, there may be a smaller chance 
of complications (infections, pain, etc.) following the biopsy 
and better temporary quality of life outcomes. However, in 
the MR-guided approach, men are locally-anaesthetized and 
may suffer embarrassment or anxiety. Therefore, a disutility of 
0.035 for all biopsy types was applied in the model. Due to the 
significant uncertainty of this estimate, these disutilities were 
varied in sensitivity analyses.
TABLE 11: KEY INPUTS USED IN THE MARKOV MODEL FOR THE mpMRI ANALYSIS
Model probabilities & source Value 95% CI Source
Baseline characteristics
Proportion biopsy naive 88% – Thompson (2014) [53];
Starting age 60 yrs – Assumption. Median baseline age = 62.4 
years in Thompson (2014) [53]
Model duration 30 yrs – Assumption. Life-time model, tested over 
10 and 20 years
Disease characteristics
Cancer prevalence 61% 53%, 69% Thompson (2014) [53]; 92/150
Probability of developing PCa after a negative biopsy 
during PSA follow-up (annual)
9.7% – Gann (2010) [55]; 465 out of 1871 patients 
over 2.8 years after previous biopsy
% Very low /low risk PCa 45% 35%, 55% Thompson (2014) [53]; 41/92
% Int/high risk PCa 55% 45%, 65% Thompson (2014) [53]; 51/92 with 36/92 int 
risk and 15/92 high risk (i.e. 39%, 16%)
Diagnostic accuracy 
Sensitivity: mpMRI scan 76% 66%, 84% Meta-analysis by de Rooij (2014), ref std 
=biopsy (p.345) [60]
Specificity: mpMRI scan 86% 79%, 91% Meta-analysis by de Rooij (2014), ref std 
=biopsy (p.345) [60]
Sensitivity: MRGB for very low/low-risk PCa 47% 17%, 79% Schoots (2014) [45]; n=1657a 
Sensitivity: MRGB for int/high-risk PCa 94% 84%, 98% Thompson (2014) [53]; 48/51, similar to 
Schoots (93%)
Sensitivity: TRUS-gb for very low/low-risk PCa 87% 74%, 94% Schoots (2014) [45]; n=1657a
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TABLE 11: KEY INPUTS USED IN THE MARKOV MODEL FOR THE mpMRI ANALYSIS
Model probabilities & source Value 95% CI Source
Sensitivity: TRUS-gb for int/high-risk PCa 85% 73%, 93% Schoots (2014) [45]; n=1657a
Sensitivity: mixed biopsy for very low/low-risk PCa 73.8% As above Accuracy of TRUS and TPUS is no different 
(shen) therefore 33% sensitivity for MRGB + 
67% for TRUS - low risk PCa
Sensitivity: mixed biopsy for int/high-risk PCa 88.0% As above Accuracy of TRUS and TPUS is no different 
(shen) therefore 33% sensitivity for MRGB + 
67% for TRUS - int/high risk PCa
Probability of mortality 
Under PSA monitoring – annual probability 0.38% – ERSPC trial [56]; 355/7408 over 13 years
Costs 
mpMRI scan $570 $399, $741 MSAC Application consultation protocol [48]
MRI-guided biopsy (weighted average) $1,552 $1,086, 
$2,018
Assumption. Weighted average of MRI-in bore 
($2,349) and TRUS fusion ($755) with 50-50 
split
TRUS-guided biopsy $700 $490, $910 Includes costs of core biopsy, prophylaxis and 
complications (see Table 4)
TRUS-guided biopsy $600 Assumption
Disutility 
Any biopsy 0.035 0.020, 
0.050
Assumption – based on Zhang et al. 2012 [58, 59]
AR-DRG = Australian refined diagnosis-related group; CI = confidence interval; ERSPC = European Randomized Study of Screening 
for Prostate Cancer; gb = guided biopsy; mpMRI = multiparametric magnetic resonance imaging; MR = magnetic resonance; MRGB = 
magnetic resonance guided biopsy; MRI = magnetic resonance imaging; MSAC = Medical Services Advisory Committee; NICE = National 
Institute for Health and Care Excellence; PCa = prostate cancer; PSA = prostate-specific antigen; TRUS = transrectal ultrasound; int = 
intermediate; VCR = Victorian Cancer Registry data
a Meta-analysis results were used from the initial biopsy cohort (6 prospective studies which included Australian study by Pokorny [54]
The key outcomes of the analysis were health system costs, 
QALYs, life years and:
 —  the number of clinically significant prostate cancers 
detected; 
 —  the number of clinically insignificant prostate cancers 
detected; and
 —  the number of avoided biopsies.
Given the findings of the generic model, and the structure 
and cost inputs used with the MR strategy, the expected 
concurrent changes of the outcomes in the model are as 
follows:
 —  Costs of mpMRI scans are slightly less than a TRUS-
guided biopsy but many men in the MR strategy 
will also get MR-guided biopsy – therefore overall 
diagnosis costs are likely to be higher;
 —  Fewer biopsies will occur as men with negative mpMRI 
avoid or delay having a biopsy, men will also avoid 
decrements in health utilities (better quality of life);
 —  MR strategies will detect fewer low-risk cancers – 
associated with fewer men accruing relatively lower 
treatment costs and higher utilities; and
 —  MR strategies will find more significant cancers – 
associated with more men accruing higher costs, lower 
utilities and shorter life.
RESULTS
The results of the modelled analysis are presented in Table 12.
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TABLE 12: KEY RESULTS OF mpMRI WITH/WITHOUT MR-GUIDED BIOPSY VERSUS TRUS-GUIDED BIOPSY
Strategy 1 Strategy 2 Strategy 3 Difference Incremental cost  
per effect ratios
Means No mpMRI 
+TRUS 
mpMRI  
± MRGB
mpMRI ± TRUS/
TPUS or MRGB 
Difference 
Strategy 2 vs 1
Difference 
Strategy 3 vs 1 
Strategy  
2 vs 1
Strategy  
3 vs 1
Costs $24,203 $24,943 $24,337 $740 higher $134 higher – –
QALYs 7.82 7.70 7.77 -0.12 (negligible) -0.05 (negligible) Marginally 
inferior
Marginally 
inferior
Life years 21.90 21.90 21.97 0 -0.30 (negligible) Marginally 
inferior
$1,914 per 
life year 
gained
No. Biopsies 
(per 1000 
men)
1,440 1,140 1,100 300 avoided 340 avoided $2467 per 
biopsy 
avoided
$394 per 
biopsy 
avoided
No. 
Significant 
cancers (per 
1000 men)
530 590 550 60 more 20 more $12,333 
per 
significant 
cancer 
detected
$6,700 per 
significant 
cancer 
detected
No. 
Insignificant 
cancers (per 
1000 men)
430 380 420 50 fewer 10 fewer Inferior Inferior
LYS = life years saved; MRGB = magnetic resonance guided biopsy; mpMRI = multiparametric magnetic resonance imaging;  
MR = magnetic resonance; QALYs = quality-adjusted life years; TRUS = transrectal ultrasound
The results show that the MR strategies increase costs and 
have slightly lower QALYs compared with the no MRI and 
TRUS option. That is, both MR strategies are marginally 
inferior to the no MRI and TRUS option. Mean costs are $740 
higher; however, no additional benefits gained in terms of 
QALYs, life years are produced, and the numbers of biopsies 
avoided are relatively small. For every 1000 men tested, the 
MR strategies accurately detected up to 60 more significant 
prostate cancers and up to 50 fewer insignificant cancers.
The MR strategies were successful in more accurately 
diagnosing prostate cancer; however, it is a costly technology. 
More accurate diagnosis of significant cancers means that 
the relative QALYs compared to current practice is lower; 
however, health utility gains occurred from avoided biopsies 
were not enough to produce a net positive gain in QALYs 
for the MR strategy. It should be emphasised that the goal 
of the MR strategy is not to downshift cancers as in earlier 
detection, but rather to more accurately diagnose significant 
cancers.
One-way sensitivity analyses were performed on the variables 
in Table 11, those most relevant to the two strategies. The 
results are shown in Table 13 and Figure 9. 
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TABLE 13: RESULTS OF ONE-WAY SENSITIVITY ANALYSES OF mpMRI MODEL
mpMRI± MRGB vs TRUS mpMRI ± MRGB/TRUS/TPUS vs TRUS
Value 
tested
Incr 
costs
Incr 
QALYs
ICER Incr costs Incr 
QALYs
ICER
Base model – $740 -0.12 -$6167 $134 -0.05 -$2680
Start age 55 years 55 $728 -0.13 -$5600 $125 -0.06 -$2083
Start age 65 years 65 $756 -0.07 -$8400 $151 -0.03 -$3775
Model duration – 10 years 10 $536 -0.07 -$7657 $21 -0.04 -$525
Model duration – 20 years 20 $677 -0.11 -$6155 $92 -0.05 -$1840
Probability of cancer – low 53% $628 -0.09 -$6978 $90 -0.03 -$3000
Probability of cancer – high 69% $844 -0.14 -$6029 $175 -0.06 -$2917
mpMRI sensitivity – low 66% $539 -0.12 -$4492 $9 -0.06 -$150
mpMRI sensitivity – high 84% $901 -0.12 -$7508 $234 -0.05 -$4680
mpMRI specificity – low 79% $782 -0.12 -$6517 $160 -0.05 -$3200
mpMRI specificity – high 91% $710 -0.12 -$5917 $116 -0.05 -$2320
Sensitivity TRUS biospy low risk – low 74% $602 -0.12 -$5017 $69 -0.07 -$1021
Sensitivity TRUS biospy low risk – high 94% $819 -0.11 -$7445 $172 -0.04 -$4300
Sensitivity TRUS biospy int risk – low 73% $826 -0.16 -$5163 $132 -0.08 -$1650
Sensitivity TRUS biospy int risk – high 93% $713 -0.07 -$10186 $150 -0.02 -$7500
Sensitivity MRGB – low risk -low 17% $983 -0.18 -$5461 $214 -0.07 -$3057
Sensitivity MRGB – low risk -high 79% $481 -0.05 -$9620 $49 -0.03 -$1633
Sensitivity MRGB – int risk - low 84% $614 -0.11 -$5582 $92 -0.05 -$1840
Sensitivity MRGB – int risk - high 98% $790 -0.12 -$6583 $151 -0.05 -$3020
Cost MRI – low $399 $597 -0.12 -$4975 -$9 -0.05 $180
Cost MRI – high $741 $884 -0.12 -$7367 $278 -0.05 -$5560
Cost TRUS-guided biospy – low $490 $962 -0.12 -$8017 $319 -0.05 -$6380
Cost TRUS-guided biospy – high $910 $519 -0.12 -$4325 -$50 -0.05 $1000
Cost MRGB – low $1,086 $497 -0.12 -$4142 $53 -0.05 -$1060
Cost MRGB – high $2,018 $982 -0.12 -$8183 $215 -0.05 -$4300
Disutility MRGB – low 0.02 $740 -0.04 -$18500 $134 -0.04 -$3350
Disutility MRGB – high 0.05 $740 -0.13 -$5692 $134 -0.06 -$2233
Disutility TRUS-guided biospy – low 0.02 $740 -0.06 -$12333 $134 -0.06 -$2233
Disutility TRUS-guided biospy – high 0.05 $740 -0.11 -$6727 $134 -0.04 -$3350
ICER = incremental cost-effectiveness ratio; mpMRI = multiparametric magnetic resonance imaging; MRI = magnetic resonance imaging;  
MRGB = magnetic resonance guided biopsy; QALYs = quality-adjusted life years; TRUS = transrectal ultrasound
Bolded = more favourable cost-effectiveness scenarios for mpMRI
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Values were tested across 95% confidence intervals or 
other plausible ranges due to their uncertainty. Overall, 
the modelling conclusions were stable to variation in most 
model inputs with one exception. In virtually all results, the 
costs were higher for the MRI strategies and the QALYs were 
(negligibly) lower and therefore the TRUS strategy remained 
superior. However, the MR strategy had lower costs (by $9 per 
person) when the MRI scan unit cost was lowered to $490. 
EV = expected value; MRGB = magnetic resonance guided biopsy; MRI = magnetic resonance imaging; mpMRI = multiparametric 
magnetic resonance imaging; PCa = prostate cancer; TRUS = transrectal ultrasound
Figure 9: Tornado diagram of the most influential variables –mpMRI± MRGB versus TRUS
The ranking of the most influential values in the model are 
provided in the tornado diagrams in Figures 9 and 10. The 
critical values were the sensitivity of TRUS and MRGB to 
detect significant and insignificant cancers and the costs of 
biopsies. It should be noted that the range of values tested 
for the diagnostic accuracy of MRGB included sensitivity 
and specificity values reported in a meta-analysis (pooled 
estimates) involving mixed and prior-biopsy populations [45].
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EV = expected value; MRGB = magnetic resonance guided biopsy; MRI = magnetic resonance imaging; mpMRI = multiparametric 
magnetic resonance imaging; PCa = prostate cancer; TRUS = transrectal ultrasound
Figure 10: Tornado diagram of the most influential variables –mpMRI± MRGB/TRUS/TPUS versus TRUS 
Results of the probabilistic sensitivity analyses are provided 
in Figure 11 where it is demonstrated that at any level of 
willingness-to-pay threshold for cost per QALY gain, the 
likelihood of the mpMRI strategies being cost-effective never 
approaches that for the TRUS strategy.
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MRI = magnetic resonance imaging; TRUS = transrectal ultrasound; QALY = quality adjusted life years
Figure 11: Cost-effectiveness acceptability curves for the three strategies 
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Figures 12 and 13 illustrate the probability of the two mpMRI 
strategies being cost-effective (versus the TRUS strategy) 
based on the outputs of 5000 Monte Carlo simulations.
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Interpretation: the proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per QALY is 92.3%. 
The chance that the TRUS strategy is cost-effective is 92.3%. MpMRI was inferior to TRUS in 7.7% of simulations.mpMRI = multiparametric 
magnetic resonance imaging; QALYs = quality-adjusted life years; WTP = willingness-to-pay
Figure 12: Incremental cost-effectiveness scatter plot for TRUS vs mpMRI ± MRGB
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Interpretation: the proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per QALY is 92.3%. 
The chance that the TRUS strategy is cost-effective is 92.3%. MpMRI was inferior to TRUS in 7.7% of simulations.mpMRI = multiparametric 
magnetic resonance imaging; QALYs = quality-adjusted life years; WTP = willingness-to-pay
Figure 13: Incremental cost-effectiveness scatter plot for TRUS vs mpMRI ± MRGB/TRUS/TPUS 
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Compared with the TRUS strategy, the probability of an 
mpMRI ± MRGB strategy being cost-effective was 7.7%,  
and the mpMRI ± MRGB or TPUS or TRUS strategy was 
22.2%, based on an Australian acceptability threshold of 
$50,000 per QALY gain and the assumptions and values  
used in the model.
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DISCUSSION
This sub-study has provided information on the long-term 
expected costs and outcomes of a strategy that improves the 
diagnosis of prostate cancer in men with suspected prostate 
cancer. As expected, there were clear patient benefits in 
terms of fewer biopsies (with avoided decrements in quality 
of life), accurate diagnoses of cancer stage, and appropriate 
subsequent treatment. However, the costs are significant for 
both mpMRI scans and MR-guided biopsy compared with 
TRUS-guided biopsy. Further, what prevents this technology 
from being cost-effective is the detection of more significant 
cancers that are associated with more men accruing 
higher costs, lower utilities and shorter life expectancy. 
The detection of fewer low-risk cancers does not result in 
sufficient offset of avoided over treatment costs according to 
the current mix of treatments in Australian practice.
A recent study by de Rooij et al. (2014) of the only other 
cost-effectiveness study of mpMRI with/without MR-guided 
biopsy versus current practice with TRUS-guided biopsy, in 
biopsy naïve men, also modelled the costs and effects using 
a Markov model [44]. The de Rooij study found that mpMRI 
was cost-effective when the sensitivity of MR-guided biopsy 
exceeded 20%. They found that costs were comparable 
between groups and that QALYs were slightly higher (0.10) 
in the MR strategy but the authors stated these were highly 
uncertain [44]. There are several shortcomings of the de 
Rooij et al. (2014) study. These included: it ignored the costs 
and health utilities associated with biopsy complications, it 
ignored repeated biopsies, the specificity and sensitivity of 
MR-guided biopsy were assumed and not evidence-based, 
and it used very low probabilities of treatment of cancers 
with radical prostatectomy [44]. This is likely to account for 
the similar costs found in the two groups. In contrast, our 
study is more specific with the detailed generic model 
health states for treatment and also stratifies the MR-guided 
biopsy sensitivity and specificity by cancer risk (low and 
intermediate/high). Further, our model was 30 years in 
duration whereas the de Rooij study was 10 years long. 
Our model relied heavily on the Thompson et al. (2014) 
diagnostic study for the effectiveness of MR-guided biopsy. 
This is a relatively small study and MR-guided biopsy 
sensitivity and specificity data confidence intervals were 
wide. A large randomised controlled trial for definitive figures 
would enhance the reliability of the cost-effectiveness results 
here. A more favourable cost-effective result is likely to 
occur if over treatment is reduced and treatment of low-risk 
disease is less invasive. Consequently, any rise in the uptake 
of active surveillance in eligible men would improve its cost-
effectiveness.
A source of uncertainty with the findings of our model is the 
decision about the number of biopsies after an initial negative 
biopsy is received but PSA levels are still elevated. Whether 
there is one biopsy only or several for all men with elevated 
PSA levels in Australia is unknown and this will affect the 
biopsies avoided and costs in our model. Further research 
on this variable would assist in more accurately reflecting real 
world practice. Also, the associated health utilities for men 
undergoing biopsies are unclear until further research can 
unearth better evidence on this and whether there are any 
differences in the relative quality of life impacts of both TRUS- 
and MR-guided biopsies.
THE BOTTOM LINE
—  A strategy of mpMRI and if indicated, subsequent 
MR-guided biopsy (or TRUS or TPUS biopsies), for the 
detection of prostate cancer has clear patient benefits in 
terms of fewer biopsies, avoided decrements in quality 
of life and more accurate diagnosis of cancer, and 
appropriate subsequent treatment.
—  The mpMRI strategies were not considered cost-effective 
compared with the current TRUS strategy with the 
likelihood of cost-effectiveness being between 7.7% and 
22.2%.
—  The MR strategy does not comprise early detection. 
Preventing this technology from being cost-effective is the 
detection of more significant cancers that are associated 
with more men accruing higher costs, lower utilities and 
shorter life expectancy relative to the current practice of 
TRUS-guided biopsy.
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4.2  COST-EFFECTIVENESS ANALYSIS OF ACTIVE 
SURVEILLANCE STRATEGIES
BACKGROUND & RATIONALE
Active surveillance is a proactive management plan for 
men diagnosed with low-risk prostate cancer where close 
monitoring is undertaken, including regular biopsies, and 
curative treatment begins only when the tumour appears to 
progress. The approach has developed from concerns about 
the overtreatment of prostate cancer among men with slow 
growing or indolent tumours that would otherwise not cause 
major harm. In men diagnosed with very low- or low-risk 
cancer, active surveillance is increasingly more acceptable 
among clinicians and patients [61]. The current balance of 
evidence supports active surveillance as a safe and superior 
alternative in terms of quality of life compared with first-line 
treatment with radical prostatectomy. There also appears 
to be no clear survival advantage of current treatments 
for low-risk prostate cancer over active surveillance [62]. 
The potential advantage of active surveillance is avoided 
detriments to quality of life for men from averted surgery, 
EBRT or brachytherapy and avoidance of common treatment-
related complications that follow. However, while on active 
surveillance, some distress and anxiety does exist among 
men when faced with a ‘do nothing’ option for a diagnosis of 
cancer [63].
There remain some concerns and unanswered questions 
around this relatively new option. To date, there is no 
consensus around the criteria for selecting men into an active 
surveillance program, the exact protocol of the program 
as well as duration and the triggers or clinical indicators for 
switching to active therapy. In addition, existing programs 
suggest there are barriers to uptake due to personal 
preferences and anxiety around the initial decision. Concerns 
are also raised on the initial diagnosis made by PSA, DRE and 
TRUS-guided biopsy which are known to misclassify the risk 
of disease in some cases. It has been reasonably proposed 
that some men exhibiting tumour progression while on an 
active surveillance program may have been misclassified 
at initial biopsy [61]. PSA testing is inadequate to distinguish 
cancers that will be clinically insignificant or significant over 
time and currently this can only be determined in retrospect 
[61].
From an economic standpoint, healthcare resource use is 
expected to be reduced because active surveillance offers 
either, a delay in treatment for a proportion of men with low-
risk disease who switch to curative treatment and experience 
related side effects or, complete avoidance of treatment and 
related side effects with tumours that do not progress. Where 
outcomes are assessed in full economic evaluations such as 
cost-effectiveness analysis, quality of life improvements are 
expected from active surveillance while survival outcomes are 
expected to be the same. 
In Victoria, the proportion of men receiving no treatment for 
very low- to low-risk prostate cancer is 41% [13] which includes 
management with either active surveillance or watchful 
waiting. Compared to men receiving active surveillance, 
watchful waiting is appropriate for older men with shorter 
life expectancy and other comorbidities. Watchful waiting 
involves fewer PSA tests and no biopsies. In low-risk prostate 
cancer, the rate of annual progression to upgraded disease 
risk is 8.8% (95% CI: 6.7% to 11%) from a meta-analysis of 
26 cohorts on active surveillance programs (n=7,627) with 
median follow-up of 3.5 years [5]. In Australia, the cessation 
rate from active surveillance was 19% in men from one series 
of 154 men after mean of 2.4 years (range 0.2-7.9 years) [61].
METHODS
The objective of this study was to look at the cost-
effectiveness of three active surveillance scenarios to 
compare with current practice in Australia, that is, existing 
levels of active surveillance. The specific research questions 
of this study are:
 1.  Compared with current practice, what are the cost and 
effectiveness outcomes under increased uptake of 
active surveillance for men with very low- or low-risk 
disease?
 2.  Compared with current practice, what is the cost-
effectiveness of increased uptake in low risk and 
widening the eligibility criteria for entry into active 
surveillance by including men with early intermediate 
risk prostate cancer?
 3.  Compared with current practice, what is the cost-
effectiveness of mpMRI scan with or without MR-
guided biopsy in the first year of active surveillance to 
guide treatment decisions?
Descriptions of the four comparative groups (i.e. current 
practice and three active surveillance scenarios) are provided 
below:
 1.  Current practice: Based on TRUS biopsy and 
clinical judgement, a man is diagnosed with very 
low- or low-risk prostate cancer and may enter into 
active surveillance. In the first year, this consists of 
6-monthly DRE, 4 PSA tests and 1 TRUS-guided 
biopsy. Thereafter, the DREs remain 6-monthly, 2 PSA 
tests are taken annually and 1 TRUS-guided biopsy 
every 2 years. While on surveillance, some cancers 
will progress. The rate of progression to intermediate 
risk cancers were drawn from a study by Klotz et al. 
(2015) with the longest reported follow-up in an active 
surveillance cohort [64].
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 2.  Increased uptake scenario: This scenario is essentially 
the same as current practice with the only difference 
being an increased proportion of men entering 
active surveillance, instead of active therapies of 
prostatectomy or radiation. Surveillance is deemed to 
be underutilised and this is simply a ‘what if’ scenario 
where those eligible to enter surveillance (excluding 
those appropriate for watchful waiting) do so assuming 
no barriers exist. Currently, 41% of men diagnosed in 
Australia with very low- or low-risk prostate cancer 
receive no treatment – either watchful waiting or 
surveillance. The increased surveillance will raise this 
probability to 80%, with 60% and 100% tested in 
sensitivity analyses. 
 3.  Intermediate risk scenario: This scenario is to 
understand whether a select group of men with early 
intermediate-risk disease would be suitable for active 
surveillance. Although it may be some time before 
research can definitively inform clinicians of the 
safety and efficacy of active surveillance in this group, 
men at intermediate risk are the largest group within 
clinically-localised disease and potentially this is where 
surveillance could have the most benefit. It is difficult 
to tell the percentage of patients with more favourable 
intermediate risk as there is some subjectivity in the 
assessment. In general, patients with only one risk 
parameter are favourable [65]. Risk parameters include 
PSA between 10-20ng/ml, Gleason score 3+4; or 
T1-T2. It may be reasonable to consider patients with 
intermediate-risk disease currently treated with EBRT 
alone as those having favourable risk. In this scenario, 
we assumed that 16% of men with intermediate-risk 
disease received active surveillance instead of first-line 
radiation therapy. In all other respects, this scenario is 
the same as for current practice.
 4.  mpMRI scenario: mpMRI is thought to have an 
increasing role at various time points during prostate 
cancer management. One of these is with the active 
surveillance population by confirming the initial 
selection of men into this pathway. This scenario 
assumes that after men enter a surveillance program, 
an mpMRI is undertaken at least 6 weeks after the 
core biopsy and within the first year. A minimal gap 
of 6 weeks between TRUS-guided and MR-guided 
biopsies is necessary because of the trauma caused by 
the TRUS-guided biopsy can mimic cancer cells. If the 
mpMRI indicates intermediate-risk disease, an MR-
guided biopsy is performed. Based on these results, 
the patient may either stay on active surveillance or be 
reclassified as having intermediate-risk disease and 
follow the appropriate treatment options.
The generic model was adapted to answer the research 
questions within this analysis. The four scenarios were 
created by adding three new strategy arms alongside the 
current practice arm. For the ‘increased uptake’ strategy, 
the current practice arm was cloned with the probability of 
receiving no treatment altered. For the ‘intermediate risk 
uptake’ strategy, a surveillance option replaced the EBRT only 
option and men instead were sent into the ‘active surveillance’ 
health state. For the ‘mpMRI’ scenario, structural changes 
were made to the ‘active surveillance’ health state (Figure 14). 
Minor changes were made to the generic model structure for 
the ‘intermediate risk uptake’ scenario as mentioned above 
(Figure 15). 
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The model inputs were derived from literature searches and 
the most relevant studies. The additional inputs and sources 
are listed below in Tables 14 and 15.
In addition to these model inputs, two changes were made 
to the generic model in light of these specific research 
questions. The first involved adding an exit age for men 
on surveillance. A man on an active surveillance program 
would not remain indefinitely on this program with advancing 
age. This is consistent with the model’s entry criteria where 
men aged 75 or over would instead be on watchful waiting. 
Similarly, in the model the maximum age a man can remain 
on active surveillance is 74 years and then he would switch 
to watchful waiting. Essentially, the main difference is that he 
would stop receiving TRUS-guided biopsies bi-annually. 
TABLE 14: PROBABILITIES OF MEN ON ACTIVE SURVEILLANCE SWITCHING TO ACTIVE THERAPY 
Year % remaining in program % leaving program for 
therapy
Transition probabilities  
used in model
5 75.7% 24.3% Years 1-5: 4.86%
10 63.5% 36.5% Years 6-10: 2.44%
15 55.0% 45.0% Years 11-15: 1.7%
20 55.0% 45.0% Years 16-20: 0%
Source: Klotz et al. (2015) [64]
Figure 15: Early intermediate risk uptake of active surveillance
Note: blue arrows indicate changes from generic model
ADT = androgen deprivation therapy; EBRT = external beam radiation therapy
Treatment
Surgery
EBRT + ADT
Surgery + EBRT
Radiation
Post radiation +ADT
Post surgery +radiation
Active surveillance
Post radiation as 1st line (Intermediate-high risk)
Post surgery as 1st line (Intermediate-high risk)
4.0 OVERVIEW OF ECONOMIC EVALUATIONS 
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Brachytherapy
Surveillance candidates 
instead of EBRT
The second change involved adding a new time-dependent 
table of probabilities for men who switch to active therapy 
while on active surveillance. This data comes from a long-
term follow-up study by Klotz et al. (2015) on a prospective 
cohort of 993 patients followed for a median duration of 
6.4 years (range 0.2 to 19.8 years). The data are presented 
in Table 14. The reasons for switching were indicators of 
worsening disease (e.g. short PSA doubling time, grade 
progression, stage progression, biopsy volume increase, 
ureteral obstruction) as well as patient preferences.
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TABLE 15: KEY MODEL INPUTS FOR THE ACTIVE SURVEILLANCE SCENARIOS 
Description Value Range Source/rationale
Current scenario
Probability of no treatment (active surveillance or 
observation) in low risk
40.6% 37%-45% Evans (2013) [13]; based on 299/736
In those receiving no treatment, the probability of 
undergoing active surveillance
100% if  
<75 years
– Assumption regarding threshold age 75 
years, men 75 years and over undergo 
watchful waiting
Threshold age for active surveillance 75 years 72 - 78 years Assumption; Life expectancy and 
comorbidities would limit active 
surveillance participation
Cost of ultrasound guided biopsy $700 $490, $910 (MBS items 37219, 55600, 72825 + 
ciprofloxacin ($20) + complication cost 
(0.02 x $5276))
Cost of active surveillance in Year 1 $1,044/year $731, $1357 2 urology visits, 4 PSAs, 1 biopsy, ±30%
Cost of active surveillance after Year 1 $608/year $426, $790 2 urology visits, 2 PSAs, biopsy every  
2 years, ±30%
Increased uptake scenario
Probability of men with low-risk cancer receiving no 
treatment
80% 60%-100% Assumption; The proportions of men 
receiving active surveillance or watchful 
waiting depend on the age threshold 
(above).
Intermediate risk scenario
Probability receiving no treatment 80% 60%-100% Assumption for % all eligible 
Probability of intermediate risk entering surveillance 
program (from those being treated)
16.0% 13.9%-17.5% Evans (2013) [13]; Of all men treated, 
25.7% receive radiation (EBRT or 
brachytherapy) x 62.3% of these get 
EBRT only = 16.0%
mpMRI scenario
Cost of mpMRI scan $570 $399, $741 MSAC Protocol; ±30%
Cost of MR-guided biopsy (in-bore) $2349 $1552 MSAC Protocol; $1552 is the weighted 
average of in-bore and fusion 
techniques (see Table 11)
Probability reclassified to intermediate risk 20.3% 14.2-26.4% Vargas (2012) [66]
EBRT = external beam radiation therapy; MSAC = Medical Services Advisory Committee; mpMRI = multiparametric magnetic resonance imaging;  
MR = magnetic resonance; MBS = Medical Benefits Schedule
Costing of the mpMRI scan and MR-guided biopsy has 
significant uncertainty as they are not funded by government 
at this time. Therefore, variations in costing were tested.
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TABLE 16: KEY RESULTS OF ACTIVE SURVEILLANCE STRATEGIES
Means Current practice Increased uptake Intermediate risk 
uptake
With mpMRI
Costs $28,031 $27,316 $27,125 $28,818
QALYs 7.89 7.92 8.01 7.88
Life years 16.36 16.35 16.48 16.35
Incremental cost per QALY Referent Superior Superior Inferior
Incremental cost per LYS Referent Superior Superior Inferior
mpMRI = multiparametric magnetic resonance imaging, LYS = life years saved, QALYs = quality-adjusted life years
RESULTS
The results of the lifetime model for a cohort of men with  
a mean age of 65 years are presented in Table 16 for mean 
costs, QALYs and life years.
Compared with current practice, the results show that cost 
savings will occur in the increased uptake and intermediate 
risk uptake scenarios but the mpMRI strategy will be slightly 
more costly. QALYs are higher for the increased uptake and 
intermediate risk uptake scenarios and negligibly different 
in the mpMRI strategy. Therefore, the increased uptake and 
intermediate risk uptake scenarios are cost-effective and 
they both represent a win-win situation with cost savings and 
better patient outcomes.
In one-way sensitivity analyses, the variables of relevance 
to the active surveillance strategies are tested to see their 
influence on the results (see Table 17).
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TABLE 17: RESULTS OF ONE-WAY SENSITIVITY ANALYSES OF THE ACTIVE SURVEILLANCE SCENARIOS 
Increased uptake scenario Intermediate risk scenario mpMRI scenario
Value 
tested
Inc 
QALYs
Inc  
costs
 
ICER
Inc  
QALYs
Inc  
costs
 
ICER
Inc  
QALYs
Inc  
costs
 
ICER
Base model – 0.03 -$715 sup 0.12 -$906 sup -0.01 $787 inf
Duration 5 years 5 -0.01 -$1,237 $123K 0.01 -$1,205 sup -0.01 $615 inf
Duration 10 years 10 0.02 -$1,012 sup 0.07 -$860 sup -0.01 $775 inf
AS age threshold – low 72 yrs 0.00 -$686 sup 0.08 -$958 sup -0.01 $685 inf
AS age threshold – high 78 yrs 0.03 -$747 sup 0.14 -$940 sup -0.02 $881 inf
Cost AS Year 1 – low $731 0.03 -$751 sup 0.12 -$870 sup -0.01 $797 inf
Cost AS Year 1 – high $1357 0.03 -$681 sup 0.12 -$1,115 sup -0.01 $782 inf
Cost AS after Year 1 – low $426 0.03 -$841 sup 0.12 -$695 sup -0.01 $812 inf
Cost AS after Year 1 – high $790 0.03 -$591 sup 0.12 -$1,039 sup -0.01 $767 inf
Cost MRI – lower $399 0.03 -$809 sup 0.12 -$773 sup -0.01 $806 inf
Cost MRI – high $741 0.03 -$624 sup 0.12 -$906 sup -0.01 $772 inf
Cost TRUS – low $490 0.03 -$716 sup 0.12 -$906 sup -0.01 $645 inf
Cost TRUS – high $910 0.03 -$715 sup 0.12 -$906 sup -0.01 $933 inf
Cost MRGB – lower $1,552 0.03 -$716 sup 0.12 -$906 sup -0.01 $789 inf
Prob no tx – current, low 37% 0.03 -$782 sup 0.12 -$972 sup -0.01 $723 inf
Prob no tx – current, high 45% 0.02 -$636 sup 0.11 -$826 sup -0.02 $869 inf
Prob no tx – inc, low 60% 0.01 -$352 sup 0.10 -$542 sup -0.01 $789 inf
Prob no tx – inc, high 100% 0.04 -$1,080 sup 0.13 -$1360 sup -0.01 $789 inf
Prob reclassify – low 14.2% 0.03 -$716 sup 0.12 -$906 sup -0.01 $741 inf
Prob reclassify – high 26.4% 0.03 -$716 sup 0.12 -$906 sup -0.02 $839 inf
Prob AS if int risk – low 13.9% 0.03 -$716 sup 0.10 -$880 sup -0.01 $789 inf
Prob AS if int risk – high 17.5% 0.03 -$716 sup 0.13 -$922 sup -0.01 $790 inf
AS = active surveillance; ICER = incremental cost-effectiveness ratio; inc = incremental; inf = inferior to current practice; int = intermediate; 
mpMRI = multiparametric magnetic resonance imaging; Prob = probability; MRGB = magnetic resonance guided biopsy; MRI = magnetic 
resonance imaging; sup = superior to current practice; TRUS = transurectal ultrasound guided biopsy; tx = treatment; QALYs = quality-
adjusted life years; yrs = years
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In probabilistic sensitivity analyses, with 1000 Monte Carlo 
simulations, the incremental scatterplots are presented 
in Figures 16 to 18. These figures demonstrate that the 
likelihood of being cost-effective for the increased uptake 
scenario was 63.9%, for the intermediate risk uptake scenario 
was 75.6%, and 0.6% for the mpMRI scenario.
Interpretation: The proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per QALY is 63.9%. 
The oval is the 95% confidence ellipse. The chance that the increased uptake scenario is cost-effective is 63.9%. 
QALY = quality-adjusted life year
Figure 16: Incremental cost-effectiveness scatter plot for increased uptake 
2,500
2,000
500
0
-500
-1,000
-1,500
-2,000
-2,500
-.2
IN
C
R
E
M
E
N
TA
L
 C
O
S
T
 (
$)
.1 .15 .2-.15 .05-.1 -.05 0
INCREMENTAL QALYS
1,500
1,000
ECONOMIC MODELLING OF HEALTHCARE SERVICES FOR PROSTATE CANCER  49
Interpretation: The proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per QALY is 75.6%. 
The oval is the 95% confidence ellipse. The chance that the intermediate uptake scenario is cost-effective is 75.6%. 
QALY = quality-adjusted life year
Figure 17: Incremental cost-effective scatter plot for intermediate risk uptake
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Interpretation: The proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per QALY is 0.6%.  
The oval is the 95% confidence ellipse. 16% of dots are at the origin. The chance that the mpMRI scenario is cost-effective is 0.6%. mpMRI 
= multiparametric magnetic resonance imaging; QALY = quality-adjusted life year
Figure 18: Incremental cost-effectiveness scatter plot for mpMRI strategy
Figure 19 further illustrates that the relative proportion of 
cost-effectiveness for the four scenarios is dominated by the 
intermediate risk scenario at all cost per QALY thresholds.
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Interpretation: Relative to each other, the intermediate risk scenario and increased uptake scenario are preferred at lower  
willingness-to-pay levels of cost per QALY. 
AS = active surveillance; QALY = quality-adjusted life year
Figure 19: Cost-effectiveness acceptability curves for all strategies
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DISCUSSION
The findings of this analysis show that favourable economic 
and patient outcomes may be possible if greater uptake of 
active surveillance occurs in Australia in men with very low- 
or low-risk prostate cancer. In addition, if a small proportion 
of men with favourable intermediate-risk prostate cancer 
also underwent active surveillance, significantly more gains 
in QALYs and cost savings may occur. Increasing active 
surveillance produced a ‘win-win’ result where there were 
gains to health-related quality of life together with resource 
savings to the health system. 
Sensitivity analyses indicate that the mean cost savings could 
range from $352 to $1237 depending on other input values 
in the model. This represents a potentially large cost savings 
to the health system if applied to all new cases of men with 
low-risk prostate cancer each year (i.e. estimated 6,624 cases 
x $715 = $4.7 million). However, QALY gains were minor but 
were consistently better than the status quo ranging from 
0.01 to 0.14 in sensitivity analyses. Larger QALY gains are 
possible for the ‘intermediate risk’ uptake scenario since the 
more serious treatment effects and adverse events could be 
avoided. 
A limitation to this analysis is that it is purely exploratory and 
no actual intervention is assessed that guarantees this switch 
in current uptake levels, either directed at clinicians or their 
patients. If this had occurred, healthcare costs of delivering 
the intervention would be necessary. Currently, an National 
Health and Medical Research Council funded project for a 
randomised controlled trial of an online decision-support 
intervention is underway, specifically designed to increase 
uptake of active surveillance in Australia. A health economic 
analysis of this intervention will be forthcoming. The current 
analysis suggests that as long as the trialled intervention 
does not exceed $715 per patient, then favourable cost-
effectiveness will be preserved.
This is the first study to look at the cost-effectiveness of 
increased versus current active surveillance uptake. Other 
cost-effectiveness studies generally compare radical 
prostatectomy versus active surveillance [67-70] whereas here, 
we undertake a more realistic comparator of including the 
current mix of treatments offered to men including active 
surveillance, radical prostatectomy, EBRT or brachytherapy 
and assessing what the changes in impacts are with 
increased uptake of surveillance. In addition, our model is 
long term and we have incorporated health utilities into the 
key outcomes as preferred in economic evaluations. 
THE BOTTOM LINE
—  Doubling the current uptake of active surveillance by 
Australian men with low-risk prostate or low-risk and 
favourable intermediate-risk cancer potentially increases 
QALYs and saves healthcare costs.
—  The likelihood of cost-effectiveness for increasing uptake 
of low-risk prostate was 63.9%, and for increasing uptake 
of low-risk and a proportion of men intermediate-risk 
cancer was 75.6%. 
—  The likelihood of cost-effectiveness of using mpMRI for 
selecting men into active surveillance, in comparison to the 
other increasing uptake scenarios, was 0.6%. 
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4.3  COST-EFFECTIVENESS ANALYSIS OF PSA 
SCREENING
BACKGROUND & RATIONALE
Widespread PSA screening for early detection of prostate 
cancer in asymptomatic men is currently not recommended 
at a population level in Australia and elsewhere around the 
world. Concerns about over diagnosis of low-risk prostate 
cancer by as much as 40-50% of screen-detected cases, 
subsequent overtreatment and adverse events are believed 
to outweigh the benefits of early diagnosis of curable disease 
[1]. Two pivotal randomised clinical trials of long-term follow 
up of screened and unscreened populations provide critical 
information for this controversial topic [56, 71]. 
TABLE 18: COMPARISON OF THE ERSPC AND PLCO PROSTATE CANCER SCREENING TRIALS (13 YEARS FOLLOW-UP)
ERSPC trial PLCO trial
Key publication of latest results Andriole (2012) [71] $27,316
Setting 7 countries in Europe 10 centres in US
Population of men 55-69 years 55-74 years
Intervention PSA test 4 yearly 
DRE optional 
Annual PSA test for 6 years
Annual DRE for 4 years
Total N intervention/control 72891/89352 38340/38345
Prostate cancers detected N intervention/control 7408/6107 4250/3815
Prostate cancers detected – rate ratio 1.57 (95%CI: 1.51, 1.62) 1.12 (95%CI: 1.07, 1.17)
Prostate cancer deaths N intervention/control 355/545 158/145
Prostate cancers detected – rate ratio 0.73 (95%CI: 0.61, 0.88) a 1.09 (95%CI: 0.87, 1.36)
All deaths – rate ratio 1.00 (95%CI: 0.98, 1.02) 1.19 (95%CI: 0.83, 1.72) b
CI = confidence interval; DRE = digital rectal examination; ERSPC = European Randomized Study of Screening for Prostate Cancer;  
PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening; PSA = prostate-specific antigen
a Adjusted for attenders
b 55-74 age group
Unhelpfully though, these two trials have produced 
inconsistent results. The US Prostate, Lung, Colorectal and 
Ovarian (PLCO) Cancer Screening Trial found a 13% increase 
in prostate cancer mortality (not statistically significant) in the 
screening group after 13 years [71]. Conversely, the European 
Randomized Study of Screening for Prostate Cancer (ERSPC) 
found a statistically significant 20% fall in prostate cancer 
mortality after 13 years [56]. All-cause mortality did not differ 
between the intervention and control groups. A comparison 
of the main features of the two trials and their results are listed 
in Table 18.
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Both studies are well-respected [72], have huge samples, 
sophisticated randomisation protocols (each with equal 
intervention and control groups), long 13-year follow-ups 
and rigorous methods for blinding of death record reviews, 
high compliance of status and testing rates. The long follow 
up is likely to be too short and does not capture all expected 
deaths from prostate cancer due to the long natural history of 
this disease. 
Cancer Council Australia and Prostate Cancer Foundation of 
Australia have recently published clinical practice guidelines 
for PSA testing and early management of test-detected 
prostate cancer (2016) [1]. These guidelines were developed 
by an expert advisory panel from a range of specialist health, 
primary care disciplines and consumer representatives. In 
these guidelines, it confirms that there is insufficient evidence 
to support population-wide screening but there remains a role 
for PSA testing in clinical practice where men might request 
a test or clinicians offer a test. PSA testing is known to be an 
imprecise test with sub-optimal levels of diagnostic accuracy. 
However, over 3,300 men each year die of prostate cancer 
in Australia and in the absence of a better alternative test, 
it remains the first-line investigation for detecting prostate 
cancer alongside DRE. Confirmation of cancer is undertaken 
through biopsy and histopathology assessment. 
Source: Medicare item statistics for PSA items 66659, 66660, 66656, 66655
PSA = prostate-specific antigen
Figure 20: Number of PSA tests ordered in Australia (2005-2014)
Ultimately, the goal of screening is to prevent early deaths 
from prostate cancer, which occurs through early detection; 
detecting cancers at an early stage before they have spread 
and before the man faces a poorer prognosis. This is 
essentially the idea behind breast, cervical and colorectal 
cancer screening programs currently in place in Australia. 
The major problems of PSA screening is the diagnostic 
inaccuracy of staging the tumour, the slow growth of many 
prostate cancers (which if left alone may not cause any 
harm) and the surgical or radiation treatment options which 
are costly and produce very common and detrimental side 
effects (i.e. incontinence, erectile dysfunction and bowel 
problems) [14]. 
Each year it is estimated that 20% of Australian men aged 45 
to 74 years have a PSA test [1]. Medicare item reports indicate 
that 1.6 million PSA tests were undertaken in 2014 at a cost 
to the Australian Government of $30.2 million. However, 
as shown in Figure 20, the volume of testing has remained 
stable since 2008. With these testing levels, it is clear that 
PSA screening is occurring opportunistically or informally 
in Australia already, much the same as it is for skin cancer 
screening in primary care settings.
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Several cost-effectiveness studies have investigated the 
value of population-level PSA testing [73-76]. In general, 
these modelling studies demonstrate that the benefits of 
widespread PSA testing do not outweigh the potential harms 
of treatments and their side effects. Intuitively, for a PSA 
testing program to be viable at a population level, there needs 
to be substantial down-shifting of tumours from high-grade 
to low-grade that produce meaningful gains in survival and 
ideally less-invasive treatments with fewer side effects than 
current options. These features deal with both the survival 
and quality of life gains of PSA testing while resource costs 
also need to be acceptable to decision makers. 
Using our generic model and extending the structure, the 
purpose of this study was to assess the cost-effectiveness of 
PSA testing and investigate the main parameters of the model 
and the mix of variables that would make it cost-effective. 
Figure 21: Additional branches to generic model for the PSA screening analysis
adv = advanced; PCa = prostate cancer; PSA = prostate-specific antigen
The types of variables normally important in evaluating 
prostate screening programs include the frequency and 
duration of testing, the age of men screened, diagnostic 
accuracy, subsequent treatments, side effects and costs for 
all components involved. In this study, the 13-year ERSPC 
findings reported by Schröder (2014) provided most of the key 
inputs [56]. In agreement with the expert advisory committee of 
the recent guidelines, the ERSPC trial was chosen as a more 
robust research study because of the following: (i) ERSPC 
trial had lower contamination of screening in the control group 
(30% vs. 52% had screening in PLCO), (ii) PLCO trial had 
an overall older age distribution, (iii) 45% of the PLCO trial’s 
overall sample had a PSA test before trial randomisation, and 
(iv) ERSPC results for prostate cancer deaths were internally 
consistent across the centres in the study, despite their 
centre-level heterogeneity [1].
METHODS
The research question of this study is: What mix of 
parameters would make PSA testing to detect early-stage 
prostate cancer in asymptomatic men cost-effective?
This study relied on the generic model for the pathways of 
treatment and follow-up from the time of diagnosis. Two 
groups were compared; asymptomatic men who receive 
screening versus the current scenario of no testing, or more 
accurately, the current scenario in Australia presently with 
ad hoc testing. The model structure was altered to include 
branches for men who may or may not develop prostate 
cancer. These additions to the model structure are illustrated 
in Figure 21.
No cancer Intermediate risk
Does not develop PCa 
Advanced cancer
Very low to low risk
High risk to locally adv
Advanced disease
Very low to low risk
Death from other causes
No cancer
Intermediate risk
High risk to locally advanced
Die of other causes
Alive
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The two comparison groups in the model are:
 1.  PSA screening group: Asymptomatic men will receive 
a PSA screen at age 60 which involves a general 
practitioner (GP) visit, the PSA test and pathology 
assessment. A second screen is offered 4 years after 
the first screen. For the model duration, men will either 
be cancer-free (and remain without cancer) or have 
cancer after urology consultation and confirmatory 
biopsy. The grade of the cancer is determined from 
the trial and men will face all the usual treatment and 
follow-up care as detailed in the generic model stratified 
by cancer risk. The data on screen-detected cancers 
are based on findings from Schröder (2014) [56] and 
include all interval or missed cancers over the 13-year 
observational period of the trial. Therefore, sensitivity 
and specificity parameters have not been explicitly 
included in the model because they are directly 
incorporated in the detected prostate cancers from the 
ERSPC trial. 
 2.  No screening group: The structure of the model and 
possible prostate cancer diagnosis or not is identical to 
the PSA screening group but the proportion of detected 
cancers are different, as reported in the ERSPC trial 
data (for the ‘no screening’ group).
Table 19 presents the key variables for the additional 
branches of the PSA testing analysis. The model assumes  
a maximum of two screens per man, 4 years apart in keeping 
with the ERSPC trial. The screening age at baseline was 60 
years and this was tested at various ages. The model duration 
was lifetime up to a maximum of 90 years of age.
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TABLE 19: ADDITIONAL MODEL VALUES FOR THE PSA TESTING ANALYSIS
Model probabilities Value 95% CI Source
Frequency of screening 4 yearly – Assumption; Schröder (2014), Martin (2013) [56, 73]
Number of screens 2 1, 3 Based on Schröder (2014) mean 2.1, range 1.0-3.5 
screens per man [56]. Model assumes first screen in Year 
1 and 2nd screen in Year 5.
Screening age in years 60 50, 55, 65 yrs Assumption; Schröder (2014) median 61.1 years  
(IQR 57.9-66.1) [56]
Cost of screening $80.05 – Cost of GP $37.05 + (cost of PSA test + pathology 
$43.00)
Cost of core biopsy (TRUS) $700 $490, $910 (MBS items 37219, 55600, 72825 + ciprofloxacin  
($20) + complication cost (0.02 x $5276))
Cost of urologist consult $86 – MBS item 104 specialist consult
Incidence of cancers a
Screening group
  Proportion of low-risk cancers 4.87% 4.36%, 5.38% Schröder (2014); 4441/6838 [56] 
  Proportion of int-risk cancers 1.81% 1.50%, 2.13% Schröder (2014); 1625/6838 [56]
  Proportion of high-risk cancers 0.58% 0.40%. 0.76% Schröder (2014); 518/6838 [56]
  Proportion of advanced cancers 0.29% 0.16%, 0.41% Schröder (2014); 254/6838 [56]
No screening group
  Proportion of low-risk cancers 3.49% 3.01%, 3.97% Schröder (2014); 2543/5507 [56]
  Proportion of int-risk cancers 2.36% 1.96%, 2.76% Schröder (2014); 1711/5507 [56]
  Proportion of high-risk cancers 0.93% 0.67%, 1.18% Schröder (2014); 667/5507 [56]
  Proportion of advanced cancers 0.82% 0.58%, 1.05% Schröder (2014); 586/5507 [56]
Relative risk of overall deaths for 
screened versus unscreened groups
1.00 0.98, 1.02 Schröder (2014) [56]; This result was used to calibrate 
the model to ensure relative overall survival did not 
differ between the two groups. The background 
mortality rate (as a function of age) was increased in 
the screening group by 27%. 
Health utilities
Utility without cancer 0.85 0.90 Clemens (2014) [30]; background utility 55-64 year olds
Disutility of core biopsy (TRUS) 0.035 0.02, 0.05 Assumption; (see Table 11)
Disutility of being in PSA program 0.05 0.00, 0.07 Assumption; to account for anxiety
MBS = Medicare Benefits Schedule; CI = confidence interval; TRUS = transrectal ultrasound; PSA = prostate-specific antigen;  
IQR = interquartile range; GP = general practitioner;; int = intermediate 
a Values from Schröder (2014) were over 13 years therefore a rate to probability formula was used to convert to annual probabilities.  
The denominator in these figures exclude 570 men in screening group and 600 in the unscreened group where risk status was missing.
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Some additional changes to health utilities also occurred. 
For men who were asymptomatic and remained cancer-free, 
a normal background utility value was used (0.85) [30]. This 
was tested at 0.90 in a sensitivity analysis. A disutility was 
incurred that was associated with a core biopsy and this value 
was consistent with the mpMRI model (see Table 11). Finally 
a small disutility was attached to being in a PSA program 
among those men who were cancer-free as this might be 
attributable to anxiety or diagnostic inaccuracy. This applied 
only for five years to cover the two screens the men would 
receive.
Figure 22: Comparison of survival curves estimated in the model 
ABS = Australian Bureau of Statistics, 3302.0.55.001 - Life Tables, States, Territories and Australia, 2011-2012
A scenario analysis was also undertaken to assess PSA 
screening every two years in men aged 50-69 years, in 
accordance with the recommended protocol in the current 
guidelines [1].
In the ERSPC trial, prostate cancer mortality was statistically 
significantly lower in the screening group than in the control 
group (rate ratio 0.83 (95% CI: 0.73 to 0.94) using deaths 
per person-years. However, all-cause mortality was similar 
between groups with a rate ratio of 1.00 (95% CI: 0.98 to 
1.02). This implies that deaths from other causes were 
higher in the screening group than in the control group. To 
avoid underestimating deaths, we calibrated the model and 
increased the background mortality rate in the screening 
group by 27% to reflect the equal overall mortality rates 
across the two groups in the ERSPC trial. A comparison of the 
final survival curves used is presented in Figure 22.
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RESULTS
The results of the model outcomes are provided in Table 20.
TABLE 20: KEY OUTCOMES FOR THE PSA SCREENING MODEL
Means a PSA screening No screening Incremental difference
Costs $15,184 $17,975 -$2,798
QALYs 9.97 10.03 -0.06
Life years 21.24 21.27 -0.03
Incremental Cost per QALY $46,633 Referent –
Incremental Cost per LYS $93,267 Referent –
LYS = life years saved; QALYs = quality-adjusted life years; PSA = prostate-specific antigen
a Results are based on 5000 Monte Carlo simulations
The results of the model show that when QALYs are the 
outcome of choice, PSA screening is less expensive by 
$2,798 per person and produces slightly lower QALYs than 
no screening. The costs are lower in the PSA screening arm 
because proportionally more men experience stage migration 
to low-risk disease, which is associated with treatments 
that are less expensive than those for higher-risk disease. 
Similarly, improved quality of life outcomes due to early-stage 
disease also occurred but these improvements were eroded 
by decrements in quality of life from more biopsies and being 
in a PSA testing program.
While cost savings to the healthcare system were found for 
PSA testing over the long run, there were no notable patient 
gains in survival or QALYs. Due to the PSA screening option 
demonstrating no additional benefit for patients in terms of 
QALYs, representing both quality of life and survival in one 
metric, PSA screening cannot be viewed as cost effective.
One-way sensitivity analyses were undertaken on all key 
variables described in Table 21. The main drivers of the model 
results were the probabilities of advanced cancers detected 
in the screening and no screening groups, the starting age 
of the men entering screening and the disutility of being in a 
screening program.
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TABLE 21: RESULTS OF ONE-WAY SENSITIVITY ANALYSES ON KEY VARIABLES IN THE PSA MODEL
Value tested Inc costs Inc QALYs ICER
Base model – -$2,798 -0.06 $46,633
Starting age 50 -$3,146 0.10 Superior a
Starting age 55 -$2,993 0.02 Superior a
Protocol in guidelines [1]
PSA testing every 2 years from 50-69 years -$2,953 0.10 Superior a
More frequent testing PSA testing annually from 50-69 years -$2,438 -0.06 $40,633
Cost of TRUS-guided biopsy – low $490 -$2,804 -0.06 $46,733
Cost of TRUS-guided biopsy – high $910 -$2,754 -0.06 $45,900
Probability of cancer in screen group
Low-risk cancer – low 4.36% -$3,057 -0.05 $61,140
Low-risk cancer – high 5.38% -$2,526 -0.08 $31,575
Intermediate-risk cancer – low 1.50% -$3,225 -0.04 $80,625
Intermediate-risk cancer – high 2.13% -$2,354 -0.09 $26,156
High-risk cancer – low 0.40% -$3,231 -0.03 $107,700
High-risk cancer – high 0.76% -$2,339 -0.10 $23,390
Advanced cancer – low 0.16% -$3,187 0.00 Superior a
Advanced cancer – high 0.41% -$2,375 -0.13 $18,269
Low-risk cancer – low 3.01% -$2,589 -0.06 $43,150
Low-risk cancer – high 3.97% -$2,952 -0.06 $49,200
Intermediate-risk cancer – low 1.96% -$2,270 -0.08 $28,375
Intermediate-risk cancer – high 2.76% -$3,258 -0.04 $81,450
High-risk cancer – low 0.67% -$2,171 -0.10 $21,710
High-risk cancer – high 1.18% -$3,369 -0.02 $168,450
Advanced cancer – low 0.58% -$2,053 -0.17 $12,076
Advanced cancer – high 1.05% -$3,488 0.06 Superior a
Health utilities
Disutility of TRUS-guided biopsy – low 0.02 -$2,802 -0.06 $44,573
Disutility of TRUS-guided biopsy – high 0.05 -$2,802 -0.06 $44,609
Disutility of being in PSA program – low 0.00 -$2,780 0.13 Superior a
Disutility of being in PSA program – high 0.07 -$2,780 -0.54 $5,148
Utility when cancer-free 0.90 -$2,780 -0.06 $46,333
ICER = incremental cost-effectiveness ratio; inc = incremental; PSA = prostate-specific antigen; QALYs = quality-adjusted life years; TRUS 
= transrectal ultrasound
a This indicates that the PSA screenng strategy is superior because it is cost-saving and produces more QALYs (albeit negligibly more) than 
no screening.
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The sensitivity analyses show that most changes in variables 
do not materially affect the main results. However, when 
the probability of detecting advanced cancers in the 
screening group decreases from 0.29% to 0.16% (the lower 
95% confidence limit) or conversely increases in the non-
screening group (from 0.58% to 1.05%), PSA screening is 
cost-effective. PSA screening is also cost-effective when the 
starting age of the screening program is either 50 or 55 years 
and in the scenario of testing every two years in ages 50-69 
years. Finally, if the model assumed no disutility for being 
in a PSA screening program, PSA would be cost-effective. 
In all of these situations where PSA was cost-effective, the 
effectiveness in terms of QALYs is very small ranging from 
-0.17 to 0.13 QALY gain or one to seven weeks of additional 
good quality life over at least 30 years duration.
Interpretation: the proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per QALY is 20.0%. 
The oval is the 95% confidence ellipse. The chance that the PSA screening scenario is cost-effective is 20%. 
PSA = prostate-specific antigen; QALY = quality-adjusted life year; WTP = willingness-to-pay
Figure 23: Incremental cost-effectiveness scatter plot for PSA screening (60 year olds) 
In probability sensitivity analyses, 5000 simulations of the 
model were performed and values randomly selected from 
the parameter distributions. At an acceptability threshold of 
$50,000 per QALY, the likelihood that PSA screening was 
cost-effective was 20.0% when the starting age was 60 years 
(Figure 23) and 83.8% at 50 years (Figure 24). For the protocol 
in the guidelines of PSA testing every two years from age 50 
to 69 years, the probability of being cost-effective was 83.1%.
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Interpretation: the proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per QALY is 83.8%. 
The oval is the 95% confidence ellipse. The chance that the PSA screening scenario is cost-effective is 83.8%. 
PSA = prostate-specific antigen; QALY = quality-adjusted life year; WTP = willingness-to-pay
Figure 24: Incremental cost-effectiveness scatter plot for PSA screening (50 year olds)
In terms of life years saved, ignoring quality of life impacts, the 
probability that PSA screening was cost-effective was 43.6% 
(Figure 25).
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Interpretation: the proportion of dots to the right of the diagonal line representing the willingness-to-pay of $50,000 per LYS is 43.6%. 
The oval is the 95% confidence ellipse. The chance that the PSA screening scenario is cost-effective is 43.6%. 
LYS = life years saved; PSA = prostate-specific antigen; WTP = willingness-to-pay
Figure 25: Incremental cost-effectiveness scatter plot for PSA screening (LYS) 
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In all the above figures, virtually all dots fell below zero on the 
vertical axis meaning that PSA testing is potentially cost-
saving over the 30 year model duration.
DISCUSSION
In response to the research question of the optimal mix of 
parameters to make a PSA program cost-effective, our results 
show that offering one screen to men at age 50 years and a 
second screen four years later would produce a cost-effective 
PSA screening protocol. Similarly for two-yearly screens from 
ages 50 to 69 years. However, it should be emphasized that 
the QALY gains are small and favourable cost-effectiveness 
depends on the extent and accuracy of advanced cancers 
detected. This analysis uses data based on the ERSPC trial.
From an economic standpoint only, cost savings arise from 
PSA screening. In all sensitivity analyses, costs savings 
occurred. Therefore, PSA screening is attractive purely from  
a health system budget viewpoint. 
The model assumes full compliance to the PSA screening 
program but in the ERSPC trial, 64% of men overall were 
screened at least once. Whether the costs of PSA screening 
to all Australian men aged 50 is feasible would require a 
budget impact analysis; however, this analysis shows that 
initial costs could produce a return on investment in the 
longer term. What is more of a concern are the patient 
benefits, which are small at best and uncertain. This analysis 
indicates benefits would only occur in younger men on 
average and this assumes the yield of cancers does not 
change by age. In the ERSPC trial, the median age was 61.1 
years old and interquartile range of 57.9 to 66.1 years old.
PSA test-based screening will be more attractive if the harms 
from treatment of low-risk cancers are minimised. This is 
likely when active surveillance is increased and the harms 
and costs of overtreatment are reduced. Our model used 
US Surveillance, Epidemiology and End Results Program 
data and other studies to estimate prostate cancer deaths by 
stage. Prostate cancer mortality rates are highest in Australia 
and New Zealand but it is unclear if the rates differ by stage 
compared to other countries. If in Australia, rates of advanced 
or high-risk disease are worse than what the model currently 
estimates, PSA screening will be even more attractive at 
lowering cancer deaths through migration to low-risk disease. 
This uncertainty is not easily resolved as staging of cancers 
reported to registries in Australia are not mandatory and not 
readily available.
THE BOTTOM LINE
—  A PSA screening program for asymptomatic men at 
age 60 years is not cost-effective at current treatment 
options in Australia, based on findings from the European 
Randomized Study of Screening for Prostate Cancer. 
—  The scenario of offering one PSA test to screen for 
prostate cancer in asymptomatic men at age 50 years,  
and a second screen four years later, would produce 
a cost-effective PSA screening program. Similarly, 
two-yearly screens from ages 50-69 is also a cost-
effective option. However, in both these strategies, very 
small QALYs are gained with no improvements to life 
expectancy.
—  Subject to caveats, the likelihood of cost-effectiveness  
of a PSA testing program for asymptomatic men at age 50, 
with a maximum of two PSA tests, is 83.8%.
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APPENDIX 1: SEARCH STRATEGIES FOR 
MODEL DEVELOPMENT
GOALS 
 1.  To obtain Australian research projects on prostate 
cancer patterns of care; and 
 2.  To obtain studies of cost-effectiveness analyses on 
treatments for prostate cancer.
TIMEFRAME 
 —  Goal 1: 2005 onwards (last 10 years) to ensure 
contemporary research
 —  Goal 2: 2000 onwards to capture earlier economy 
studies
SEARCH STRATEGY
To ensure that all relevant studies were identified, 
comprehensive searches of the published literature were 
conducted. The following approach was used:
 1.  A search of published literature databases using OVID 
SP for Medline and PubMed databases
 2.  A search of HTA databases using International Network 
of Agencies of Health Technology Assessment, 
Database of Abstracts of Reviews and Effects and 
Centre  
of Reviews and Dissemination CRD
 3.  A search of trials and systematic reviews using The 
Cochrane Library, International Clinical Trials Registry 
Platform and clinicaltrials.gov
The search was conducted on 20-22 January 2015.
INCLUSION CRITERIA
 1.  Studies were selected if they related to prostate cancer 
in Australia (i.e., patterns of care, diagnostic and 
therapeutic tests), from 2005 onwards.
 2.  Studies were selected if cost-effectiveness analysis, 
cost-benefit analysis, cost-utility analysis or economic 
evaluation mentioned in title or abstract, from 2000 
onwards and not limited to country.
EXCLUSION CRITERIA 
Wrong time period
 —  Pre 2005 PCa Australia
 —  Pre 2000 CEA
Wrong study 
 —  Not related to patient management (Diagnose, AS, 
WW, Survivorship, palliative) or
 —  Not related to intervention/outcome (surgery (RP), 
radiotherapy (EBRT or brachytherapy), hormone 
therapy (ADT) and chemotherapy) or
 —  Wrong population (not PCa) or
 —  Not Australian (for Goal 1.)
KEYWORDS
 —  Prostate cancer, Australia
MESH TERMS 
 —  [Prostatic neoplasms], [Australia] 
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SEARCH RESULTS — OVID SP
PROSTATE CANCER AUSTRALIA
No. Query Results
#1 Prostate cancer.mp OR Prostatic Neoplasms[MeSH] 109,671
#2 Prostate AND (cancer* OR carcinoma* OR malignanc* OR tumo#r* OR neoplas*).mp 106,807
#3 1 OR 2 122,546
#4 3 and Australia.cp 1,438
#5 Australia*.mp OR Australia [MeSH] 137,811
#6 3 AND 5 662
#7 4 OR 6 1,905
#8 Limit 7 to (yr =“2005-Current” AND “all adult (19 plus years)”) 685
HTA DATABASES: INAHTA, DARE AND CRD
 —  DARE and CRD: 622 articles found (search terms: 
prostate cancer 2005-2015)
TRIALS AND SYSTEMATIVE REVIEWS
 —  Cochrane Library: 30 articles found (search terms: 
prostate cancer)
 —  International Trials Registry: 169 imported 
(search terms: prostate cancer and Australia) NCT trials 
excluded (60)
 —  Clinical trials.gov: 87 studies (search terms: prostate 
cancer Australia) included
SUMMARY
 — Total articles found:  1607
 —  Duplicates removed:  22 
Therefore left with:  1571 
(60 from Clinical Trials Registry were on NCT 
clinicaltrials.gov)
— Excluded: not relevant to research question
— Wrong study:  546
— Wrong time period:  159
— Studies left after exclusions:  864
STUDIES INCLUDED:
1.  PCA Australia:  168 
 Chemotherapy:  6
 Detection/Diagnosis:  24
 Hormone Therapy (ADT):  13
 Management (AS or WW or palliative):  5
 Multiple therapies (usually RT plus ADT):  6
 Pyschological:  25
 QoL:  3
 Radiotherapy (EBRT or brachytherapy):  22
 Surgery (RP or orchidectomy or robotic laproscopy):  13
 Working folder:  52
2. CEA PCa:   67 studies 
 Bisphosphonates:   5
 Chemotherapy:   7
 Detection/diagnosis:   13
 Hormone therapy (ADT):   12
 Management:   4
 Radiotherapy:   14
 Steroid Therapy:   1
 Surgery:   7
 Working folder:   6
ADDITIONAL LITERATURE SEARCH (TARGET META-ANALYSIS 
AND SYSTEMATIC REVIEWS, SNOWBALLING)
 —  An additional literature search was conducted by 
Haitham which located 60 studies (incl duplicates).
 —  An additional literature search (Ovid) was conducted by 
Robbie which located 114 extra studies.
Search strategy: Prostatic Neoplasms [MeSH] AND Quality-
Adjusted Life Years [MeSH] After duplicates and studies 
before 2000 were removed, 72 studies remained for use. 
UTILITIES: CEA REGISTRY
Searched utilities for prostate cancer (accessed on 9 March 
2015): 224 results saved/100 accessed
CLINICAL GUIDELINES
Updated to endnote on 6 March 2014.
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APPENDIX 2: RESULTS OF OUT-OF-POCKET 
EXPENSES ANALYSIS
The values used in the model to represent out-of-pocket 
expenses are detailed in Table A1. There is little research to 
support these values and collection of this data from patients 
can be problematic. Recall bias is an issue and the alternative 
of cost diaries to capture every service paid for is generally 
too burdensome for men going through treatments and 
repeated doctors and clinic visits. Nevertheless, the sources 
used are reasonable to estimate these important costs for 
men.
TABLE A1: ESTIMATED OUT-OF-POCKET COSTS TO PRIVATELY INSURED MEN WITH PROSTATE CANCER 
Item Value Distribution Source and calculation
Prostate-specific antigen test $0/test – MBS items 66660 and 73928; assumed pathologist bulk bills
Urology consultation and 
digital rectal examination
$51/visit – MBS Item 104
Ultrasound guided biopsy $926/
procedure
Gamma 
(44,0.048)
Financial Impact of Prostate Cancer in Australia 2013, page 67, 
Table 4.22, based on actual expenses by one survey participant, 
added 10% to expenses due to 2009 prices. MBS items cytoscopy 
36812, needle biopsy 37219, ultrasound 55603, urologist 105, pre-
consult anaethetist 17610, 31-35 minutes 20910, urologist 105. 
Testosterone level $0/test – MBS item 66695; assumed pathologist bulk bills
Anti-androgen $37.70 – Biclutamide 50mg tab. PBS monthly price for 28 tablets
Medical androgen deprivation 
therapy 
$452.4/year – Leuprorelin acetate 22.5mg injection every three months or 
goserelin 10.8mg every three months. PBS monthly price for both 
is $37.70.
Active surveillance in Year 1 $1597/year – 2 urology visits, 4 PSA tests, 1 biopsy
Active surveillance after Year 1 $565/year – 2 urology visits, 2 PSA tests, biopsy every 2 years
Observation (watchful waiting) $76/year – 1 to 2 urology visits and PSA tests
Follow-up after treatment for 
localised disease
$61/year – Urology visit and PSA 4 times in Year 1, then 2 times in Years 2-3, 
then once a year. Averaged over the model years = $61/year. 
Follow-up with androgen 
deprivation therapy
$153/year – Urology visit, PSA and testosterone every 3 to 6 months. Assumed 
every 4 months in the model. Assumed pathologist bulk bills.
Recurrence workup $1252/
workup
– Urology visit, biopsy and bone scans
Bone scans $275/image Gamma 
(44,0.162)
2013 Financial Impact of Prostate Cancer in Australia, page 67, 
Table 4.22, based on actual expenses by one survey participant, 
added 10% to expenses due to 2009 prices.
Second-line chemotherapy $37.70/month – Abiraterone 1g daily (4 tablets of 250mg), cost/mth = $37.70.
Cabazitaxel 25mg/m2 (for BSA 1.8m2), cost/mth = $37.70.
Enzalutamide capsules, cost per month $37.70 
Average monthly cost = $37.70.
It should be noted that these costs relate to men who 
are privately insured and treated in a private hospital. 
Publicly treated men would not pay anything for services 
in hospital including surgery, biopsies, radiation therapies, 
chemotherapy and imaging services. All patients would 
pay for out-of-hospital services such as GP and urologist 
consultations, x-rays and scans (in community radiology 
clinics) and also co-payments for medications and 
incontinence aids. Often PSA and other pathology tests are 
bulk-billed and here we assume no out-of-pocket expense.  
A limitation of this analysis is that palliative care costs have 
not been included due to a lack of data on this. 
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TABLE A1: ESTIMATED OUT-OF-POCKET COSTS TO PRIVATELY INSURED MEN WITH PROSTATE CANCER 
Item Value Distribution Source and calculation
Treating incontinence $406/year Gamma 
(44,0.109)
2013 Financial Impact of Prostate Cancer in Australia, page 67, 
Table 4.22, based on actual expenses by one survey participant, 
added 10% to expenses due to 2009 prices
Radical prostatectomy $6,567 Gamma 
(44,0.007)
2013 Financial Impact of Prostate Cancer in Australia, page 38, 
Table 4.5, based on analysis of Medicare data
External beam radiation 
therapy 
$1,658 Gamma 
(44,0.027)
As above
Low-dose rate brachytherapy $7,251 Gamma 
(44,0.006)
As above
Palliative care $0 – Excluded this from the analysis
Supportive care for androgen 
deprivation therapy
$914/year Gamma 
(44,0.049)
Includes zoledronic acid at 4mg every 3 to 4 weeks ($37.70 for 4 
months; PBS DPMQ) + calcium and vitamin D ($30/month) + DEXA 
scan at $102 (MBS item 12306).
First-line chemotherapy $312/cycle Gamma 
(44,0.14v
Cost of docetaxel 75mg/m2 + prednisone 5mg, for BSA of 1.8m2 
every 3 weeks; the cycle cost $37.70 (PBS ) + $65 administration 
cost (MBS item 13915) + $5 premedication cost (dexamethasone 
tablets) + $20 Blood test + $50 complication cost (febrile 
neutropenia in 3% of patients at $ 1,700 per episode).
BSA = body surface area; DEXA = dual energy X-ray absorptiometry; MBS = Medicare Benefits Schedule; DPMQ = dispensed price for maximum quantity;  
PBS = Pharmaceutical Benefits Scheme; PSA = prostate-specific antigen
TABLE A2: OUT-OF-POCKET EXPENSES FOR HEALTHCARE ESTIMATED OVER REMAINING LIFE a
Mean cost (SD) 
Base case (discounted) $9,150 ($611)
Base case, undiscounted $10,679 ($669)
Cohorts with different mean age b:
  50 years mean $11,586 ($734)
  55 years mean $10,928 ($696)
  60 years mean $10,140 ($665)
  70 years mean $7,896 ($547)
  75 years mean $5,588 ($468)
  80 years mean $5,158 ($455)
Stage of disease
Localised cancer $9,249 ($626)
  Very low / low risk $10,201 ($711)
  Intermediate risk $8,673 ($652)
  High risk to locally advanced $9,166 ($570)
Advanced cancer $6,274 ($481)
SD = standard deviation
a All figures are from probabilistic sensitivity analysis outcomes from 1000 Monte Carlo simulations. 
b The base case uses a mean of age 65 years.
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The results show that there was little difference in out-
of-pocket costs for those with the three risk levels within 
localised disease. Furthermore, there was little difference 
among men 50, 55, 60 or 65 years (base case)of age and  
this starts to drop as men are older.
Figure A1: Cumulative out-of-pocket costs for men with prostate cancer by disease stage
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